U.S. patent application number 15/138647 was filed with the patent office on 2016-08-11 for hepatitis b virus vaccines.
The applicant listed for this patent is Altravax, Inc.. Invention is credited to Clayton W. Beard, Hakima Sbai, Robert Gerald Whalen, Li Xu.
Application Number | 20160229897 15/138647 |
Document ID | / |
Family ID | 51625230 |
Filed Date | 2016-08-11 |
United States Patent
Application |
20160229897 |
Kind Code |
A1 |
Whalen; Robert Gerald ; et
al. |
August 11, 2016 |
HEPATITIS B VIRUS VACCINES
Abstract
This document provides methods and materials for producing
immune responses against hepatitis B viruses. For example,
polypeptides, nucleic acid molecules encoding such polypeptides,
virus-like particles containing such polypeptides, vaccine
preparations containing one or more polypeptides provided herein,
vaccine preparations containing one or more nucleic acid molecules
provided herein, vaccine preparations containing one or more
virus-like particles provided herein, and methods for inducing
immune responses against hepatitis B viruses within mammals (e.g.,
humans) are provided.
Inventors: |
Whalen; Robert Gerald;
(Foster City, CA) ; Beard; Clayton W.; (Chapel
Hill, NC) ; Xu; Li; (Cupertino, CA) ; Sbai;
Hakima; (Providence, RI) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Altravax, Inc. |
Sunnyvale |
CA |
US |
|
|
Family ID: |
51625230 |
Appl. No.: |
15/138647 |
Filed: |
April 26, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14207135 |
Mar 12, 2014 |
9353158 |
|
|
15138647 |
|
|
|
|
61785838 |
Mar 14, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 2039/53 20130101;
A61P 31/20 20180101; C12N 7/00 20130101; C07K 14/005 20130101; C12N
2730/10122 20130101; C12N 2730/10134 20130101 |
International
Class: |
C07K 14/005 20060101
C07K014/005; C12N 7/00 20060101 C12N007/00 |
Claims
1-5. (canceled)
6. A nucleic acid molecule comprising a nucleic acid sequence
encoding a polypeptide comprising an amino acid sequence, wherein
said amino acid sequence is at least 97 percent identical to the
amino acid sequence set forth in SEQ ID NO:18.
7. The nucleic acid molecule of claim 6, wherein said amino acid
sequence is at least 98 percent identical to the amino acid
sequence set forth in SEQ ID NO:18.
8. The nucleic acid molecule of claim 6, wherein said amino acid
sequence is at least 99 percent identical to the amino acid
sequence set forth in SEQ ID NO:18.
9. A nucleic acid molecule comprising a nucleic acid sequence
encoding a polypeptide comprising an amino acid sequence, wherein
said amino acid sequence is at least 96 percent identical to the
amino acid sequence set forth in SEQ ID NO:14.
10. The nucleic acid molecule of claim 9, wherein said amino acid
sequence is at least 97 percent identical to the amino acid
sequence set forth in SEQ ID NO:14.
11. The nucleic acid molecule of claim 9, wherein said amino acid
sequence is at least 98 percent identical to the amino acid
sequence set forth in SEQ ID NO:14.
12. The nucleic acid molecule of claim 9, wherein said amino acid
sequence is at least 99 percent identical to the amino acid
sequence set forth in SEQ ID NO:14.
13. A nucleic acid molecule comprising a nucleic acid sequence
encoding a polypeptide comprising an amino acid sequence, wherein
said amino acid sequence is at least 97 percent identical to the
amino acid sequence set forth in SEQ ID NO:22.
14. The nucleic acid molecule of claim 13, wherein said amino acid
sequence is at least 98 percent identical to the amino acid
sequence set forth in SEQ ID NO:22.
15. The nucleic acid molecule of claim 13, wherein said amino acid
sequence is at least 99 percent identical to the amino acid
sequence set forth in SEQ ID NO:22.
16. A nucleic acid molecule comprising a nucleic acid sequence
encoding a polypeptide comprising an amino acid sequence, wherein
said amino acid sequence is at least 95 percent identical to the
amino acid sequence set forth in SEQ ID NO:28.
17. The nucleic acid molecule of claim 16, wherein said amino acid
sequence is at least 96 percent identical to the amino acid
sequence set forth in SEQ ID NO:28.
18. The nucleic acid molecule of claim 16, wherein said amino acid
sequence is at least 97 percent identical to the amino acid
sequence set forth in SEQ ID NO:28.
19. The nucleic acid molecule of claim 16, wherein said amino acid
sequence is at least 98 percent identical to the amino acid
sequence set forth in SEQ ID NO:28.
20. The nucleic acid molecule of claim 16, wherein said amino acid
sequence is at least 99 percent identical to the amino acid
sequence set forth in SEQ ID NO:28.
21. A nucleic acid molecule comprising a nucleic acid sequence
encoding a polypeptide comprising an amino acid sequence, wherein
said amino acid sequence is at least 96 percent identical to the
amino acid sequence set forth in SEQ ID NO:12.
22. The nucleic acid molecule of claim 21, wherein said amino acid
sequence is at least 97 percent identical to the amino acid
sequence set forth in SEQ ID NO:12.
23. The nucleic acid molecule of claim 21, wherein said amino acid
sequence is at least 98 percent identical to the amino acid
sequence set forth in SEQ ID NO:12.
24. The nucleic acid molecule of claim 21, wherein said amino acid
sequence is at least 99 percent identical to the amino acid
sequence set forth in SEQ ID NO:12.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 14/207,135, filed Mar. 12, 2014, which claims the benefit of
U.S. Provisional Application Ser. No. 61/785,838, filed Mar. 14,
2013. The disclosure of the prior applications are considered part
of (and are incorporated by reference in) the disclosure of this
application.
BACKGROUND
[0002] 1. Technical Field
[0003] This document relates to methods and materials for producing
immune responses against hepatitis B viruses. For example, this
document provides vaccines (e.g., nucleic acid vaccines, virus-like
particle vaccines, and polypeptide vaccines) capable of being
administered to mammals (e.g., humans) under conditions that induce
production of immune responses against hepatitis B viruses.
[0004] 2. Background Information
[0005] Hepatitis B virus (HBV) is a hepadnavirus that causes an
inflammatory illness of the liver. About a third of the world
population is infected at one point in their lives, and about 350
million people are chronic carriers. The virus can be transmitted
by exposure to infectious blood or body fluids. The acute illness
causes liver inflammation, vomiting, jaundice, and, in rare cases,
death. Chronic hepatitis B infections may cause cirrhosis and liver
cancer.
SUMMARY
[0006] This document provides methods and materials for producing
immune responses against hepatitis B viruses. For example, this
document provides vaccines (e.g., nucleic acid vaccines, virus-like
particle vaccines, and polypeptide vaccines) capable of being
administered to mammals (e.g., humans) under conditions that induce
production of immune responses against hepatitis B viruses as well
as methods for producing immune responses against hepatitis B
viruses within a mammal (e.g., a human).
[0007] As described herein, polypeptides having the amino acid
sequence set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26,
28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58
(or a sequence at least about 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or 100 percent identical to such as sequence)
can be produced and formulated into a vaccine preparation having
the ability to produce an immune response against hepatitis B
viruses when administered to a mammal (e.g., a human). Such vaccine
preparations can be administered to a mammal prior to the mammal
being exposed to hepatitis B viruses. In such cases, the
administered vaccine preparation can provide increased protection
against hepatitis B virus infection. In some cases, such vaccine
preparations can be administered to a mammal after the mammal is
infected with hepatitis B virus (e.g., an acutely hepatitis B virus
infected or chronically hepatitis B virus infected mammal). In such
cases, administration of the vaccine preparation can be used to
treat the hepatitis B virus infection. For example, administration
of a vaccine preparation provided herein to a mammal infected with
hepatitis B virus can result in a reduction in hepatitis B viral
load, a reduction in the severity of the symptoms of the hepatitis
B virus infection, a reduction in the degree of liver cirrhosis, a
reduction in the incidence of hepatocellular cancer, or a clearance
of the hepatitis B virus from the liver.
[0008] In some cases, a polypeptide provided herein (e.g., a
polypeptide having the amino acid sequence set forth in SEQ ID
NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40,
42, 44, 46, 48, 50, 52, 54, 56, or 58, or an amino acid sequence
that is at least about 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99, or 100 percent identical to the amino acid sequence set
forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32,
34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58) can be
formulated into virus-like particles that can be used as vaccine
preparations having the ability to produce an immune response
against hepatitis B viruses when administered to a mammal (e.g., a
human). The vaccine preparations containing such virus-like
particles can be administered to a mammal prior to the mammal being
exposed to hepatitis B viruses. In such cases, the administered
vaccine preparation containing virus-like particles can provide
increased protection against hepatitis B virus infection. In some
cases, a vaccine preparation containing a virus-like particle
provided herein can be administered to a mammal after the mammal is
infected with hepatitis B virus (e.g., an acutely hepatitis B virus
infected or chronically hepatitis B virus infected mammal). In such
cases, administration of the vaccine preparation containing a
virus-like particle can be used to treat the hepatitis B virus
infection. For example, administration of a vaccine preparation
containing a virus-like particle provided herein to a mammal
infected with hepatitis B virus can result in a reduction in
hepatitis B viral load, a reduction in the severity of the symptoms
of the hepatitis B virus infection, a reduction in the degree of
liver cirrhosis, a reduction in the incidence of hepatocellular
cancer, or a clearance of the hepatitis B virus from the liver.
[0009] As also described herein, nucleic acid molecules encoding a
polypeptide having the amino acid sequence set forth in SEQ ID
NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40,
42, 44, 46, 48, 50, 52, 54, 56, or 58 (or a sequence at least about
86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100
percent identical to such as sequence) can be obtained and
formulated into a nucleic acid vaccine preparation having the
ability to express the encoded polypeptide and produce an immune
response against hepatitis B viruses when administered to a mammal
(e.g., a human). Such nucleic acid vaccine preparations can be
administered to a mammal prior to the mammal being exposed to
hepatitis B viruses. In such cases, the administered nucleic acid
vaccine preparation can provide increased protection against
hepatitis B virus infection. In some cases, such nucleic acid
vaccine preparations can be administered to a mammal after the
mammal is infected with hepatitis B virus (e.g., an acutely
hepatitis B virus infected or chronically hepatitis B virus
infected mammal). In such cases, administration of the nucleic acid
vaccine preparation can be used to treat the hepatitis B virus
infection. For example, administration of a nucleic acid vaccine
preparation provided herein to a mammal infected with hepatitis B
virus can result in a reduction in hepatitis B viral load, a
reduction in the severity of the symptoms of the hepatitis B virus
infection, a reduction in the degree of liver cirrhosis, a
reduction in the incidence of hepatocellular cancer, or a clearance
of the hepatitis B virus from the liver.
[0010] Having the ability to use the vaccine preparations provided
herein produce immune responses against hepatitis B viruses can
allow clinicians to provide their patients with increased
protection against hepatitis B virus infections. In addition, the
vaccine preparations provided herein can allow clinicians to treat
patients previously infected with hepatitis B virus.
[0011] In general, one aspect of this document features a
polypeptide comprising an amino acid sequence that is at least 97
percent identical (e.g., at least 98, 99, or 100 percent identical)
to the amino acid sequence set forth in SEQ ID NO:10.
[0012] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 96 percent
identical (e.g., at least 97, 98, 99, or 100 percent identical) to
the amino acid sequence set forth in SEQ ID NO:12.
[0013] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 96 percent
identical (e.g., at least 97, 98, 99, or 100 percent identical) to
the amino acid sequence set forth in SEQ ID NO:14.
[0014] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 95 percent
identical (e.g., at least 96, 97, 98, 99, or 100 percent identical)
to the amino acid sequence set forth in SEQ ID NO:16.
[0015] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 97 percent
identical (e.g., at least 98, 99, or 100 percent identical) to the
amino acid sequence set forth in SEQ ID NO:18.
[0016] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 93 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:20.
[0017] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 97 percent
identical (e.g., at least 98, 99, or 100 percent identical) to the
amino acid sequence set forth in SEQ ID NO:22.
[0018] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 89 percent
identical (e.g., at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
or 100 percent identical) to the amino acid sequence set forth in
SEQ ID NO:24.
[0019] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 89 percent
identical (e.g., at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
or 100 percent identical) to the amino acid sequence set forth in
SEQ ID NO:26.
[0020] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 95 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:28.
[0021] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 94 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:30.
[0022] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 96 percent
identical (e.g., at least 97, 98, 99, or 100 percent identical) to
the amino acid sequence set forth in SEQ ID NO:32.
[0023] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 96 percent
identical (e.g., at least 97, 98, 99, or 100 percent identical) to
the amino acid sequence set forth in SEQ ID NO:34.
[0024] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 96 percent
identical (e.g., at least 97, 98, 99, or 100 percent identical) to
the amino acid sequence set forth in SEQ ID NO:36.
[0025] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 93 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:38.
[0026] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 97 percent
identical (e.g., at least 98, 99, or 100 percent identical) to the
amino acid sequence set forth in SEQ ID NO:40.
[0027] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 93 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:42.
[0028] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 93 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:44.
[0029] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 95 percent
identical (e.g., at least 96, 97, 98, 99, or 100 percent identical)
to the amino acid sequence set forth in SEQ ID NO:46.
[0030] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 96 percent
identical (e.g., at least 97, 98, 99, or 100 percent identical) to
the amino acid sequence set forth in SEQ ID NO:48.
[0031] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 93 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:50.
[0032] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 93 percent
identical (e.g., at least 94, 95, 96, 97, 98, 99, or 100 percent
identical) to the amino acid sequence set forth in SEQ ID
NO:52.
[0033] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 92 percent
identical (e.g., at least 93, 94, 95, 96, 97, 98, 99, or 100
percent identical) to the amino acid sequence set forth in SEQ ID
NO:54.
[0034] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 86 percent
identical (e.g., at least 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99, or 100 percent identical) to the amino acid sequence
set forth in SEQ ID NO:56.
[0035] In another aspect, this document features a polypeptide
comprising an amino acid sequence that is at least 89 percent
identical (e.g., at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
or 100 percent identical) to the amino acid sequence set forth in
SEQ ID NO:58.
[0036] Any one of the polypeptides described in the above 25
paragraphs can comprise the ability to induce an immune response
against a hepatitis B virus when the polypeptide is administered to
a mammal. In some cases, any one of the polypeptides described in
the above 25 paragraphs can be a fusion polypeptide comprising a
second amino acid sequence. The second amino acid sequence can
encode a tag selected from the group consisting of GST, FLAG, GFP,
and c-myc. The second amino acid sequence can encode a cytokine
selected from the group consisting of GM-CSF, IL-2, and IL-12. The
polypeptide can be substantially pure. The polypeptide can be an
isolated polypeptide.
[0037] In another aspect, this document features a virus-like
particle comprising one or more polypeptides selected from the
group consisting of the polypeptides described in the above said 25
paragraphs. The virus-like particle can comprise one polypeptide
selected from the group. The virus-like particle can comprise two,
three, four, or five different polypeptides selected from the
group. The virus-like particle can comprise the ability to induce
an immune response against a hepatitis B virus when the particle is
administered to a mammal.
[0038] In another aspect, this document features a vaccine
preparation comprising one or more polypeptides selected from the
group consisting of the polypeptides described in the above said 25
paragraphs. The vaccine preparation can comprise one polypeptide
selected from the group. The vaccine preparation can comprise two,
three, four, or five different polypeptides selected from the
group. The vaccine preparation can comprise the ability to induce
an immune response against a hepatitis B virus when the vaccine
preparation is administered to a mammal. The vaccine preparation
can comprise an adjuvant. The adjuvant can be selected from the
group consisting of aluminum-based compounds, Montanide ISA 51,
Montanide ISA 720, and CpG oligodeoxynucleotides. The adjuvant can
comprise alum or Al.sub.2O.sub.3.
[0039] In another aspect, this document features a nucleic acid
molecule comprising a nucleic acid sequence encoding a polypeptide
selected from the group consisting of the polypeptides described in
the above said 25 paragraphs. The nucleic acid molecule can
comprise a promoter sequence operably linked to the nucleic acid
sequence. The nucleic acid molecule can be a vector. The vector can
be a plasmid. The vector can be a viral vector. The viral vector
can be selected from the group consisting of adenoviral vectors,
adeno-associated virus vectors, and vaccinia viral vectors.
[0040] In another aspect, this document features a vaccine
preparation comprising one or more nucleic acid molecules. The
nucleic acid molecule comprises a nucleic acid sequence encoding a
polypeptide selected from the group consisting of the polypeptides
described in the above said 25 paragraphs. The nucleic acid
molecule can comprise a promoter sequence operably linked to the
nucleic acid sequence. The nucleic acid molecule can be a vector.
The vector can be a plasmid. The vector can be a viral vector. The
viral vector can be selected from the group consisting of
adenoviral vectors, adeno-associated virus vectors, and vaccinia
viral vectors. The vaccine preparation can comprise a nucleic acid
molecule comprising a nucleic acid sequence encoding one
polypeptide selected from the group. The vaccine preparation can
comprise one or more nucleic acid molecules comprising a nucleic
acid sequence encoding two, three, four, or five different
polypeptides selected from the group. The vaccine preparation can
comprise the ability to induce an immune response against a
hepatitis B virus when the vaccine preparation is administered to a
mammal and the polypeptide is expressed within the mammal. The
vaccine preparation can comprise an adjuvant. The adjuvant can be
selected from the group consisting of aluminum-based compounds,
Montanide ISA 51, Montanide ISA 720, and CpG oligodeoxynucleotides.
The adjuvant can comprise alum or Al.sub.2O.sub.3.
[0041] In another aspect, this document features a method for
inducing an immune response against a hepatitis B virus within a
mammal. The method comprises administering a vaccine preparation to
the mammal. The vaccine preparation comprises (a) one or more
polypeptides selected from the group consisting of the polypeptides
described in the above said 25 paragraphs, (b) one or more
virus-like particles comprising one or more polypeptides selected
from the group consisting of the polypeptides described in the
above said 25 paragraphs, or (c) one or more nucleic acid molecules
comprising a nucleic acid sequence encoding a polypeptide selected
from the group consisting of the polypeptides described in the
above said 25 paragraphs. The mammal can be a human. The mammal can
be a human not previously infected with a hepatitis B virus. The
mammal can be a human acutely infected with a hepatitis B virus.
The mammal can be a human chronically infected with a hepatitis B
virus. The immune response can comprise the production of
anti-hepatitis B virus antibodies. The method can comprise
administering a second vaccine preparation to the mammal after the
step of administering the vaccine preparation to the mammal,
wherein the second vaccine preparation comprises an hepatitis B
virus antigen. The method can comprise administering a second
vaccine preparation to the mammal after the step of administering
the vaccine preparation to the mammal, wherein the second vaccine
preparation comprises (a) one or more polypeptides selected from
the group consisting of the polypeptides described in the above
said 25 paragraphs, (b) one or more virus-like particles comprising
one or more polypeptides selected from the group consisting of the
polypeptides described in the above said 25 paragraphs, or (c) one
or more nucleic acid molecules comprising a nucleic acid sequence
encoding a polypeptide selected from the group consisting of the
polypeptides described in the above said 25 paragraphs.
[0042] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention pertains.
Although methods and materials similar or equivalent to those
described herein can be used to practice the invention, suitable
methods and materials are described below. All publications, patent
applications, patents, and other references mentioned herein are
incorporated by reference in their entirety. In case of conflict,
the present specification, including definitions, will control. In
addition, the materials, methods, and examples are illustrative
only and not intended to be limiting.
[0043] The details of one or more embodiments of the invention are
set forth in the accompanying drawings and the description below.
Other features, objects, and advantages of the invention will be
apparent from the description and drawings, and from the
claims.
DESCRIPTION OF THE DRAWINGS
[0044] FIG. 1 is a schematic of the strategy used in designing the
strain-specific oligonucleotide primers used to keep the `a`
epitope loop constrained during the DNA shuffling reaction. Thirty
nucleotides of the HBV (strain ayw) `a` loop sequence were held
constant and flanked by fifteen nucleotides on each side derived
from the related HBs genes of chimpanzee/gibbon, woodchuck, and
woolly monkey. A restriction endonuclease BsrB I site sequence
(CCGCTC) was introduced in the sequence encoding the HBV "a"
loop.
[0045] FIG. 2 shows the positive (+) strain oligonucleotide
sequences used to hold the HBV "a` loop sequence constant during
DNA shuffling. A restriction endonuclease BsrB I site sequence
(CCGCTC) was introduced, and a BspM I site sequence (ACCTGCN4) was
knocked out by the two conservative changes shown in lower case (t
and c). These altered restriction sites were engineered into the
oligonucleotides to enable a rapid evaluation of oligo
incorporation by restriction analysis. The conserved 30 nucleotides
from the AYW `a` epitope loop are shown above the dashed line and
underlined in the sequences below the dashed line. All primers are
positive sense as indicated by (+). Primers shown: chibbon (+)
primer (chimpanzee/gibbon); WM (+) primer (woolly monkey); WD (+)
primer (woodchuck).
[0046] FIG. 3 shows representative ELISA data from primary
screening of a first shuffled library are shown. Anti-Hepatitis B
antibody levels present in the sera of mice injected with clones
from the first shuffled library were measured by ELISA and
expressed as milli-International Units per mL. A reference level
typically used is the highest antibody level induced in mice by a
positive-control DNA vaccine (measured as mIU/mL using a commercial
anti-HBsAg detection kit). The striped bar indicates antibody
levels induced by a wild-type clone. The black bars indicate
antibody levels above reference value induced by shuffled
clones.
[0047] FIG. 4 contains a listing of the nucleic acid sequence and
amino acid sequence for one of the human parental clone used in the
initial shuffling.
[0048] FIG. 5 contains a listing of the nucleic acid sequence and
amino acid sequence for one of the woolly monkey parental clone
used in the initial shuffling.
[0049] FIG. 6 contains a listing of the nucleic acid sequence and
amino acid sequence for one of the human/woodchuck parental clone
used in the initial shuffling.
[0050] FIG. 7 contains a listing of the nucleic acid sequence and
amino acid sequence for one of the composite chimpanzee-gibbon
parental clone used in the initial shuffling.
[0051] FIG. 8 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6101 obtained from the initial
shuffling.
[0052] FIG. 9 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6102 obtained from the initial
shuffling.
[0053] FIG. 10 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6103 obtained from the initial
shuffling.
[0054] FIG. 11 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6104 obtained from the initial
shuffling.
[0055] FIG. 12 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6105 obtained from the initial
shuffling.
[0056] FIG. 13 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6106 obtained from the initial
shuffling.
[0057] FIG. 14 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6107 obtained from the initial
shuffling.
[0058] FIG. 15 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6108 obtained from the initial
shuffling.
[0059] FIG. 16 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6109 obtained from the initial
shuffling.
[0060] FIG. 17 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6111 obtained from the initial
shuffling.
[0061] FIG. 18 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6201 obtained from a second
shuffling.
[0062] FIG. 19 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6202 obtained from a second
shuffling.
[0063] FIG. 20 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6203 obtained from a second
shuffling.
[0064] FIG. 21 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6204 obtained from a second
shuffling.
[0065] FIG. 22 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6205 obtained from a second
shuffling.
[0066] FIG. 23 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6206 obtained from a second
shuffling.
[0067] FIG. 24 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6207 obtained from a second
shuffling.
[0068] FIG. 25 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6208 obtained from a second
shuffling.
[0069] FIG. 26 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6209 obtained from a second
shuffling.
[0070] FIG. 27 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6210 obtained from a second
shuffling.
[0071] FIG. 28 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6211 obtained from a second
shuffling.
[0072] FIG. 29 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6212 obtained from a second
shuffling.
[0073] FIG. 30 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6213 obtained from a second
shuffling.
[0074] FIG. 31 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6214 obtained from a second
shuffling.
[0075] FIG. 32 contains a listing of the nucleic acid sequence and
amino acid sequence for clone 6215 obtained from a second
shuffling.
[0076] FIG. 33 is a nucleic acid sequence alignment of the four
parental clones encoding hepatitis surface antigen proteins
obtained from HBV, woolly monkey hepatitis virus (WMHV),
human/woodchuck hepatitis virus (HWHV, and chimpanzee-gibbon
hepatitis virus (CGHV), and the indicated clones.
[0077] FIG. 34 is an amino acid sequence alignment of the hepatitis
surface antigen proteins encoded by the four parental clones from
HBV, woolly monkey hepatitis virus (WMHV), human/woodchuck
hepatitis virus (HWHV), and chimpanzee-gibbon hepatitis virus
(CGHV), and the indicated clones.
[0078] FIG. 35 contains a wild-type hepatitis B virus sequence with
a summary of the differences observed in clones 6101-6109, 6111,
and 6201-6215.
[0079] FIG. 36 contains a diagram of a vector used to express HBsAg
clones.
[0080] FIG. 37. Geometric Mean Titers (GMT) of anti-HBsAg obtained
with first round clones. Geometric Mean Titers .+-.SEM of
anti-HBsAg were measured by ELISA in sera obtained by immunizing
test groups of mice each with one of ten improved clones selected
as inducing the highest expression levels in the initial screening
procedure. The clone names are shown on the X axis. HBV is a
plasmid used as a control that wild-type hepatitis B envelope
gene-containing plasmid used as a control.
[0081] FIG. 38. Geometric Mean Titers of anti-HBsAg obtained with
second round clones. A second round library was obtained by
shuffling the ten improved clones selected from the first round
library. One of ten second round library clones selected based on
their induction of anti-HBsAg levels, or the wild-type human
hepatitis B envelope gene (HBV), was used to immunize each group of
mice. Geometric Mean Titers of anti-HBsAg in the sera from the
immunized mice were measured by ELISA. The clone names are shown on
the X axis; each bar represents one group of mice. The Y-axis shows
the geometric mean titer .+-.SEM of anti-HBsAg for each group in
International units.
[0082] FIG. 39 is a bar graph plotting the GMT (mIU/mL) for the
indicated clones when administered to 30 six-week old C57BL/6
mice.
[0083] FIG. 40 is a bar graph plotting the GMT (mIU/mL) for the
indicated clones when administered to mice alone (DNA prime; gray)
or when administered to mice prior to the mice receiving a boost
with wild-type protein (Protein Boost; black). The bars labeled
"Engerix" are from groups of mice that received one protein
injection (gray bar) or the initial priming protein injection
followed by the boosting injection (black bar).
[0084] FIG. 41 is a bar graph plotting the GMT (mIU/mL) for the
indicated clones when administered to outbred mice.
[0085] FIG. 42 is a bar graph plotting the GMT (mIU/mL) for the
indicated clones when administered to non-responder mice.
DETAILED DESCRIPTION
[0086] This document provides methods and materials for producing
immune responses against hepatitis B viruses. For example, this
document provides polypeptides, nucleic acid molecules encoding
such polypeptides, virus-like particles containing such
polypeptides, vaccine preparations containing one or more
polypeptides provided herein, vaccine preparations containing one
or more nucleic acid molecules provided herein, vaccine
preparations containing one or more virus-like particles provided
herein, and methods for inducing immune responses against hepatitis
B viruses within mammals (e.g., humans).
[0087] As described herein, a polypeptide provided herein can be
designed to include the amino acid sequence as set forth in SEQ ID
NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40,
42, 44, 46, 48, 50, 52, 54, 56, or 58 (or an amino acid sequence
that is at least about 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99, or 100 percent identical to the amino acid sequence set
forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32,
34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58). Such
polypeptides can be used to induce an immune response against
hepatitis B viruses within a mammal. In some cases, a polypeptide
provided herein can have the amino acid sequence as set forth in
SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,
38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58 and can have the
identity to SEQ ID NO:2, 4, 6, and 8 as indicated in Table 1.
TABLE-US-00001 TABLE 1 Percentages of amino acid residues of the
indicated clones that are identical to those of the indicated
parental clones. Clone SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID No.
NO:.sup.a NO: 2.sup.b NO: 4.sup.c NO: 6.sup.d NO: 8.sup.e 6101 10
87.6 96.9 59.7 78.5 6102 12 95.6 88.1 60.6 82.9 6103 14 95.6 88.1
62.8 80.3 6104 16 95.1 92.0 60.2 78.5 6105 18 96.5 88.1 60.6 82.9
6106 20 92.9 90.7 62.8 78.5 6107 22 96.9 87.6 61.5 80.3 6108 24
88.1 84.1 65.6 79.4 6109 26 88.1 84.1 65.6 79.4 6111 28 94.7 92.5
61.9 77.6 6201 30 93.4 91.2 60.2 79.4 6202 32 95.6 87.2 61.1 83.3
6203 34 95.1 92.0 60.2 78.5 6204 36 95.1 92.0 60.2 78.5 6205 38
92.5 91.2 60.6 79.4 6206 40 96.0 89.4 61.5 82.0 6207 42 92.5 90.3
62.4 78.1 6208 44 92.9 86.3 62.8 81.6 6209 46 94.2 87.6 61.1 84.2
6210 48 95.1 92.5 61.1 78.5 6211 50 92.5 91.2 60.6 79.4 6212 52
92.0 91.6 60.2 78.9 6213 54 91.6 91.2 61.1 82.9 6214 56 84.5 85.0
65.6 72.4 6215 58 88.9 87.6 67.0 77.6 .sup.aprovided SEQ ID NO: is
for the amino acid sequence of the indicated clone number.
.sup.bSEQ ID NO: 2 is the amino acid sequence for the human
parental clone. .sup.cSEQ ID NO: 4 is the amino acid sequence for
the woolly monkey parental clone. .sup.dSEQ ID NO: 6 is the amino
acid sequence for the human/woodchuck parental clone. .sup.eSEQ ID
NO: 8 is the amino acid sequence for the chimpanzee/gibbon parental
clone.
[0088] In some cases, a polypeptide provided herein can be an
isolated polypeptide. The term "isolated" as used herein with
reference to polypeptides refers to (a) a polypeptide that is not
associated with proteins that such polypeptide is normally
associated with in nature or (b) a polypeptide that does not occur
or exist in nature.
[0089] In some cases, a polypeptide provided herein can be a
substantially pure polypeptide. The term "substantially pure" as
used herein with reference to polypeptides refers to a polypeptide
preparation that is substantially free of other polypeptides,
lipids, carbohydrates, and nucleic acid. In some cases, a
substantially pure polypeptide can be a polypeptide that is at
least 60 percent pure or is a chemically synthesized polypeptide. A
substantially pure polypeptide can be at least about 60, 65, 70,
75, 80, 85, 90, 95, or 99 percent pure. Typically, a substantially
pure polypeptide will yield a single major band on a non-reducing
polyacrylamide gel.
[0090] In some cases, a polypeptide provided herein can include the
amino acid sequence as set forth in SEQ ID NO:10, 12, 14, 16, 18,
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52,
54, 56, or 58 except that the amino acid sequence includes a
variation (e.g., a substitution, addition, or deletion) at one or
more positions (e.g., one, two, three, four, five, six, seven,
eight, nine, ten, eleven, twelve, 13, 14, 15, 16, 17, 18, 19, 20,
or more positions). Such variant sequences, e.g., those having one
or more amino acid substitutions relative to the amino acid
sequence set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26,
28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58,
can be prepared and modified as described herein. For example, a
polypeptide provided herein can include the amino acid sequence as
set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30,
32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58 except
that the amino acid sequence includes a conservative or
non-conservative amino acid substitution at one or more positions
(e.g., one, two, three, four, five, six, seven, eight, nine, ten,
eleven, twelve, 13, 14, 15, 16, 17, 18, 19, 20, or more positions).
In some cases, an amino acid substitution can be made by selecting
substitutions that do not differ significantly in their effect on
maintaining (a) the structure of the peptide backbone in the area
of the substitution, (b) the charge or hydrophobicity of the
molecule at a particular site, or (c) the bulk of the side chain.
For example, naturally occurring residues can be divided into
groups based on side-chain properties: (1) hydrophobic amino acids
(methionine, alanine, valine, leucine, and isoleucine); (2) neutral
hydrophilic amino acids (cysteine, serine, and threonine); (3)
acidic amino acids (aspartic acid and glutamic acid); (4) basic
amino acids (asparagine, glutamine, histidine, lysine, and
arginine); (5) amino acids that influence chain orientation
(glycine and proline); and (6) aromatic amino acids (tryptophan,
tyrosine, and phenylalanine). Substitutions made within these
groups can be considered conservative substitutions. Non-limiting
examples of substitutions include, without limitation, substitution
of valine for alanine, lysine for arginine, glutamine for
asparagine, glutamic acid for aspartic acid, serine for cysteine,
asparagine for glutamine, aspartic acid for glutamic acid, proline
for glycine, arginine for histidine, leucine for isoleucine,
isoleucine for leucine, arginine for lysine, leucine for
methionine, leucine for phenylalanine, glycine for proline,
threonine for serine, serine for threonine, tyrosine for
tryptophan, phenylalanine for tyrosine, and/or leucine for
valine.
[0091] Further examples of conservative substitutions that can be
made at any position within the amino acid sequence set forth in
SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,
38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58 include, without
limitation, those set forth in Table 2.
TABLE-US-00002 TABLE 2 Examples of conservative amino acid
substitutions. Original Residue Exemplary substitutions Ala Val,
Leu, Ile Arg Lys, Gln, Asn Asn Gln, His, Lys, Arg Asp Glu Cys Ser
Gln Asn Glu Asp Gly Pro His Asn, Gln, Lys, Arg Ile Leu, Val, Met,
Ala, Phe Leu Ile, Val, Met, Ala, Phe Lys Arg, Gln, Asn Met Leu,
Phe, Ile Phe Leu, Val, Ile, Ala Pro Gly Ser Thr Thr Ser Trp Tyr Tyr
Trp, Phe, Thr, Ser Val Ile, Leu, Met, Phe, Ala
[0092] In some case, an amino acid sequence used to make a
polypeptide provided herein can include one or more
non-conservative substitutions. Non-conservative substitutions
typically entail exchanging a member of one of the classes
described above for a member of another class.
[0093] In some cases, a polypeptide provided herein can have an
amino acid sequence with at least 90% (e.g., at least 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity
to a reference sequence (e.g., SEQ ID NO:10, 12, 14, 16, 18, 20,
22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54,
56, or 58). Percent sequence identity is calculated by determining
the number of matched positions in aligned amino acid sequences
(target amino acid sequence aligned to an identified amino acid
sequence), dividing the number of matched positions by the number
of amino acids of the identified amino acid sequence (e.g., SEQ ID
NO:10), and multiplying by 100. A matched position refers to a
position in which identical amino acids occur at the same position
in aligned amino acid sequences. Percent sequence identity also can
be determined for nucleic acid sequences.
[0094] Percent sequence identity is determined by comparing a
target amino acid sequence to the identified amino acid sequence
(e.g., SEQ ID NO:10) using the ClustalW alignment tool provided in
the Geneious software platform (version 6.05, Biomatters Ltd,
Auckland, New Zealand).
[0095] Any appropriate method can be used to obtain a polypeptide
provided herein. For example, common polypeptide purification
techniques such as affinity chromatography and HPLC as well as
polypeptide synthesis techniques can be used. In addition, any
appropriate material can be used as a source to obtain a
polypeptide provided herein. For example, cultured cells engineered
to over-express a particular polypeptide provided herein (e.g., a
cell line designed to include a nucleic acid molecule provided
herein) can be used to produce a polypeptide provided herein. Such
cells can be prokaryotic cells (e.g., bacterial cells such as E.
coli, Bacillus subtilis, or Pseudomonas cells) or eukaryotic cells
(e.g., yeast cells such as Saccharomyces cerevisiae, Hansenula
polymorpha or Pichia pastoris cells, insect cells such as
Drosophila melanogaster (e.g., Schneider 2 or Schneider 3 cells),
Spodoptera frugiperda, or Trichoplusia ni cells, or mammalian cells
such as CHO, HEK 293, MRC, or PER-C6 cells). In some cases, a
polypeptide provided herein can be designed to contain an amino
acid sequence that allows the polypeptide to be captured onto an
affinity matrix. For example, a tag such as c-myc, hemagglutinin,
polyhistidine, Flag.TM. tag (Kodak), Strep-Tag, V5, or VSV-G can be
used to aid polypeptide purification. Such tags can be inserted
anywhere alone a polypeptide including at either the carboxyl or
amino termini.
[0096] In some cases, a polypeptide provided herein can be a fusion
polypeptide. Such a fusion polypeptide can include one or more
additional amino acid sequences in addition to the amino acid
sequence as set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24,
26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or
58 (or an amino acid sequence that is at least about 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent
identical to the amino acid sequence set forth in SEQ ID NO:10, 12,
14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46,
48, 50, 52, 54, 56, or 58). The additional amino acid sequences can
be the amino acid sequence of a tag as described above, a marker
such as GFP or Luciferase, an enzyme such as alkaline phosphatase
or GST, or a cytokine such as GM-CSF, IL-2, or IL-12, or a
chemokine such as IP-10, MCP-3, or RANTES.
[0097] This document also provides nucleic acid molecules that
encode a polypeptide provided herein. The term "nucleic acid" as
used herein encompasses both RNA and DNA, including cDNA, genomic
DNA, and synthetic (e.g., chemically synthesized) DNA. The nucleic
acid can be double-stranded or single-stranded. Where
single-stranded, the nucleic acid can be the sense strand or the
antisense strand. In addition, nucleic acid can be circular or
linear.
[0098] The term "isolated" as used herein with reference to nucleic
acid refers to a naturally-occurring nucleic acid that is not
immediately contiguous with both of the sequences with which it is
immediately contiguous (one on the 5' end and one on the 3' end) in
the naturally-occurring genome of the organism or virus from which
it is derived. For example, an isolated nucleic acid can be,
without limitation, a recombinant DNA molecule of any length,
provided one of the nucleic acid sequences normally found
immediately flanking that recombinant DNA molecule in a
naturally-occurring genome is removed or absent. Thus, an isolated
nucleic acid includes, without limitation, a recombinant DNA that
exists as a separate molecule (e.g., a cDNA or a genomic DNA
fragment produced by PCR or restriction endonuclease treatment)
independent of other sequences as well as recombinant DNA that is
incorporated into a vector, an autonomously replicating plasmid, a
virus (e.g., a retrovirus, adenovirus, or herpes virus), or into
the genomic DNA of a prokaryote or eukaryote. In addition, an
isolated nucleic acid can include a recombinant DNA molecule that
is part of a hybrid or fusion nucleic acid sequence.
[0099] The term "isolated" as used herein with reference to nucleic
acid also includes any non-naturally-occurring nucleic acid since
non-naturally-occurring nucleic acid sequences are not found in
nature and do not have immediately contiguous sequences in a
naturally occurring genome. For example, non-naturally-occurring
nucleic acid such as an engineered nucleic acid is considered to be
isolated nucleic acid. Engineered nucleic acid can be made using
common molecular cloning or chemical nucleic acid synthesis
techniques. Isolated non-naturally-occurring nucleic acid can be
independent of other sequences, or incorporated into a vector, an
autonomously replicating plasmid, a virus (e.g., a retrovirus,
adenovirus, or herpes virus), or the genomic DNA of a prokaryote or
eukaryote. In addition, a non-naturally-occurring nucleic acid can
include a nucleic acid molecule that is part of a hybrid or fusion
nucleic acid sequence.
[0100] It will be apparent to those of skill in the art that a
nucleic acid existing among hundreds to millions of other nucleic
acid molecules within, for example, cDNA or genomic libraries, or
gel slices containing a genomic DNA restriction digest is not to be
considered an isolated nucleic acid.
[0101] A nucleic acid molecule provided herein (e.g., an isolated
nucleic acid molecule) can encode any of the polypeptides provided
herein. For example, a nucleic acid molecule provided herein can
encode a polypeptide having the amino acid sequence as set forth in
SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,
38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58 (or an amino acid
sequence that is at least about 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or 100 percent identical to the amino acid
sequence set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26,
28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58).
Examples of such nucleic acid molecules include, without
limitation, nucleic acid molecules that have the nucleic acid
sequence set forth in SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25,
27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, or 57.
In some cases, nucleic acid molecule provided herein can be
codon-optimized to express the encoded polypeptide in cells of a
particular species (e.g., codon-optimized for expression in
bacterial cells, yeast cells, insect cells, fungal cells, algal
cells, mammalian cells, or human cells). For example, a nucleic
acid molecule provided herein encoding a polypeptide having the
amino acid sequence set forth in SEQ ID NO:10 can include a
codon-optimized version of the nucleic acid sequence set for in SEQ
ID NO:9.
[0102] In some cases, a nucleic acid molecule provided herein can
be a vector. A vector can be is a replicon, such as a plasmid,
phage, virus, or cosmid, into which another DNA segment may be
inserted so as to bring about the replication of the inserted
segment. An "expression vector" is a vector that includes one or
more expression control sequences. An "expression control sequence"
is a sequence (e.g., a DNA sequence) that controls or regulates the
transcription and/or translation of another sequence (e.g., another
DNA sequence).
[0103] In expression vectors, a nucleic acid molecule provided
herein (e.g., a nucleic acid encoding a polypeptide provided
herein) can be operably linked to one or more expression control
sequences. As used herein, "operably linked" means incorporated
into a genetic construct so that expression control sequences
effectively control expression of a coding sequence of interest.
Examples of expression control sequences include promoters,
enhancers, and transcription terminating regions. A promoter is an
expression control sequence composed of a region of a DNA molecule,
typically within 100 to 500 nucleotides upstream of the point at
which transcription starts (generally near the initiation site for
RNA polymerase II). To bring a coding sequence under the control of
a promoter, the translation initiation site of the translational
reading frame of the polypeptide can be positioned between one and
about fifty nucleotides downstream of the promoter. Enhancers
provide expression specificity in terms of time, location, and
level. Unlike promoters, enhancers can function when located at
various distances from the transcription site. An enhancer also can
be located downstream from the transcription initiation site. A
coding sequence is "operably linked" and "under the control" of
expression control sequences in a cell when RNA polymerase is able
to transcribe the coding sequence into mRNA, which then can be
translated into the polypeptide encoded by the coding sequence.
[0104] Suitable expression vectors include, without limitation,
plasmids and viral vectors derived from, for example,
bacteriophage, baculoviruses, tobacco mosaic virus, herpes viruses,
cytomegalovirus, retroviruses, vaccinia viruses, adenoviruses, and
adeno-associated viruses. Numerous vectors and expression systems
are commercially available from such corporations as
Invitrogen/Life Technologies (Carlsbad, Calif.).
[0105] An expression vector can include a tag sequence designed to
facilitate subsequent manipulation of the expressed nucleic acid
sequence (e.g., purification or localization). Tag sequences, such
as green fluorescent protein (GFP), glutathione S-transferase
(GST), polyhistidine, c-myc, hemagglutinin, or Flag.TM. tag (Kodak,
New Haven, Conn.) sequences typically are expressed as a fusion
with the encoded polypeptide. Such tags can be inserted anywhere
within the polypeptide including at either the carboxyl or amino
terminus.
[0106] A nucleic acid molecule provided herein can be obtained
using any appropriate method including, without limitation, common
molecular cloning and chemical nucleic acid synthesis techniques.
For example, PCR can be used to obtain a nucleic acid containing a
nucleic acid sequence sharing similarity to a nucleic acid molecule
provided herein, and common mutagenesis techniques can be used to
introduce desired nucleotide additions, deletions, substitutions,
or combinations thereof into the obtained nucleic acid. PCR refers
to a procedure or technique in which target nucleic acid is
amplified in a manner similar to that described in U.S. Pat. No.
4,683,195, and subsequent modifications of the procedure described
therein. Generally, sequence information from the ends of the
region of interest or beyond are used to design oligonucleotide
primers that are identical or similar in sequence to opposite
strands of a potential template to be amplified. Using PCR, a
nucleic acid sequence can be amplified from RNA or DNA. For
example, a nucleic acid sequence can be isolated by PCR
amplification from total cellular RNA, total genomic DNA, and cDNA
as well as from bacteriophage sequences, plasmid sequences, viral
sequences, and the like. When using RNA as a source of template,
reverse transcriptase can be used to synthesize complimentary DNA
strands.
[0107] This document also provides virus-like particles that
include one or more of the polypeptides provided herein. For
example, a virus-like particle provided herein can be designed to
include a polypeptide having the amino acid sequence as set forth
in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34,
36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58 (or an amino acid
sequence that is at least about 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or 100 percent identical to the amino acid
sequence set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26,
28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58).
In some cases, a single virus-like particle can include more than
one different polypeptide provided herein. For example, a single
virus-like particle provided herein can include both a polypeptide
having the amino acid sequence as set forth in SEQ ID NO:16 and a
polypeptide having the amino acid sequence as set forth in SEQ ID
NO:24. Other combinations of polypeptides that can be used to make
virus-like particles having a collection of different polypeptides
include, without limitation, those set forth in Table 3.
TABLE-US-00003 TABLE 3 Combinations of polypeptides for virus-like
particles (VLPs). Sequence identifiers of polypeptides VLP ID No.
to be included in the VLP 7101 14, 16, 18 7102 22, 24, 28 7103 14,
16, 18, 22, 24 7104 36, 38 7105 32, 52, 58 7106 32, 36, 38, 52, 58
7107 14, 16, 36, 38 7108 22, 24, 28, 32, 52, 58 7109 16, 18, 24,
32, 36, 38, 52, 58
[0108] Any appropriate method can be used to make virus-like
particles provided herein. For example, a virus-like particle
provided herein can be made using a method described elsewhere.
See, e.g., U.S. Pat. No. 4,803,164, which describes a method to
produce HBs-containing VLPs in yeast cells; U.S. Pat. No.
6,551,820, which describes a method to produce HBs-containing VLPs
in transgenic plants; and European Patent Application No. EP0241021
A2, which describes a method to produce HBs-containing VLPs in
Chinese Hamster Ovary cells or normal liver cells.
[0109] This document also provides vaccine preparations for
inducing an immune response within a mammal against a hepatitis B
virus. In some cases, a vaccine preparation provided herein can
include one or more of the polypeptides provided herein. For
example, a vaccine preparation provided herein can be designed to
include a polypeptide having the amino acid sequence as set forth
in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34,
36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58 (or an amino acid
sequence that is at least about 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, 99, or 100 percent identical to the amino acid
sequence set forth in SEQ ID NO:10, 12, 14, 16, 18, 20, 22, 24, 26,
28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, or 58).
In some cases, a single vaccine preparation can include more than
one different polypeptide provided herein. For example, a single
vaccine preparation provided herein can include both a polypeptide
having the amino acid sequence as set forth in SEQ ID NO:16 and a
polypeptide having the amino acid sequence as set forth in SEQ ID
NO:24. Other combinations of polypeptides that can be used to make
a vaccine preparation having a collection of different polypeptides
include, without limitation, those set forth in Table 4.
TABLE-US-00004 TABLE 4 Combinations of polypeptides for vaccine
preparations. Vaccine Sequence identifiers of polypeptides to ID
No. be included in the vaccine preparation 8101 14, 16, 18 8102 22,
24, 28 8103 14, 16, 18, 22, 24 8104 36, 38 8105 32, 52, 58 8106 32,
36, 38, 52, 58 8107 14, 16, 36, 38 8108 22, 24, 28, 32, 52, 58 8109
16, 18, 24, 32, 36, 38, 52, 58
[0110] In some cases, a vaccine preparation provided herein can
include one or more of the nucleic acid molecules provided herein.
For example, a vaccine preparation provided herein can be designed
to include a nucleic acid vector having a promoter operably linked
to a nucleic acid sequence that encodes a polypeptide having the
amino acid sequence as set forth in SEQ ID NO:10, 12, 14, 16, 18,
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52,
54, 56, or 58 (or an amino acid sequence that is at least about 86,
87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent
identical to the amino acid sequence set forth in SEQ ID NO:10, 12,
14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46,
48, 50, 52, 54, 56, or 58). In some cases, a single vaccine
preparation can include more than one different nucleic acid
molecule provided herein. For example, a single vaccine preparation
provided herein can include both a nucleic acid vector designed to
express a polypeptide having the amino acid sequence as set forth
in SEQ ID NO:16 and a nucleic acid vector designed to express a
polypeptide having the amino acid sequence as set forth in SEQ ID
NO:24. Other combinations of vectors that can be used to make a
vaccine preparation having a collection of different vectors
include, without limitation, those set forth in Table 5. In some
cases, a single nucleic acid vector can encode two or more
polypeptides provided herein. For example, a single nucleic acid
vector can be designed to encode a combination of polypeptides as
set forth in Table 4.
TABLE-US-00005 TABLE 5 Combinations of vectors for vaccine
preparations. Sequence identifiers of polypeptides Vaccine to be
encoded by individual vectors ID No. included in the vaccine
preparation 9101 14, 16, 18 9102 22, 24, 28 9103 14, 16, 18, 22, 24
9104 36, 38 9105 32, 52, 58 9106 32, 36, 38, 52, 58 9107 14, 16,
36, 38 9108 22, 24, 28, 32, 52, 58 9109 16, 18, 24, 32, 36, 38, 52,
58
[0111] In some cases, a vaccine preparation provided herein can
include one or more of the virus-like particles provided herein.
For example, a vaccine preparation provided herein can be designed
to include a virus-like particle that includes a polypeptide having
the amino acid sequence as set forth in SEQ ID NO:10, 12, 14, 16,
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,
52, 54, 56, or 58 (or an amino acid sequence that is at least about
86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100
percent identical to the amino acid sequence set forth in SEQ ID
NO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40,
42, 44, 46, 48, 50, 52, 54, 56, or 58). In some cases, a single
vaccine preparation can include more than one different virus-like
particles provided herein. For example, a single vaccine
preparation provided herein can include both a virus-like particle
that includes a polypeptide having the amino acid sequence as set
forth in SEQ ID NO:16 and a virus-like particle that includes a
polypeptide having the amino acid sequence as set forth in SEQ ID
NO:24. Other combinations of virus-like particles that can be used
to make a vaccine preparation having a collection of different
virus-like particles include, without limitation, those set forth
in Table 6.
TABLE-US-00006 TABLE 6 Combinations of VLPs for vaccine
preparations. Vaccine Specific VLPs to be included ID No. in the
vaccine preparation 10101 VLP ID#7101, VLP ID#7102 10102 VLP
ID#7104, VLP ID#7105 10103 VLP ID#7101, VLP ID#7104 10104 VLP
ID#7102, VLP ID#7105 10105 VLP ID#7101, VLP ID#7102, VLP ID#7104,
VLP ID#7105 10106 VLP ID#7103, VLP ID#7106 10107 VLP ID#7101, VLP
ID#7104, VLP ID#7105
[0112] Any appropriate method can be used to formulate a vaccine
preparation provided herein (e.g., a polypeptide vaccine, nucleic
acid vaccine, or VLP vaccine provided herein). For example, a
polypeptide vaccine provided herein, a nucleic acid vaccine
provided herein, or a VLP vaccine provided herein can be formulated
to include one or more adjuvants. An adjuvant can be an
immunological compound that can enhance an immune response against
a particular antigen such as a polypeptide provided herein.
Suitable adjuvants include, without limitation, alum as well as
other aluminum-based compounds (e.g., Al.sub.2O.sub.3) that can be
obtained from various commercial suppliers. For example,
REHYDRAGEL.RTM. adjuvants can be obtained from Reheis Inc.
(Berkeley Heights, N.J.). REHYDRAGEL.RTM. adjuvants are based on
crystalline aluminum oxyhydroxide, and are hydrated gels containing
crystalline particles with a large surface area (about 525
m.sup.2/g). Their Al.sub.2O.sub.3 content typically ranges from
about 2 percent to about 10 percent. Rehydragel LG, for example,
has an Al.sub.2O.sub.3 content of about 6 percent, and flows
readily upon slight agitation. Rehydragel LG also has a protein
binding capacity of 1.58 (i.e., 1.58 mg of bovine serum albumin
bound per 1 mg of Al.sub.2O.sub.3), a sodium content of 0.02
percent, a chloride content of 0.28 percent, undetectable sulphate,
an arsenic level less than 3 ppm, a heavy metal content less than
15 ppm, a pH of 6.5, and a viscosity of 1090 cp. Rehydragel LG can
be combined with a polypeptide solution (e.g., a polypeptide in
PBS) to yield Al(OH).sub.3. In some cases, ALHYDROGEL.TM., an
aluminum hydroxy gel adjuvant (Alhydrogel 1.3%, Alhydrogel 2.0%, or
Alhydrogel "85") obtained from Brenntag Stinnes Logistics, can be
used.
[0113] In some cases, Montanide ISA 51 can be included in a vaccine
preparation provided herein. MN51 (MONTANIDE.RTM. Incomplete SEPPIC
Adjuvant (ISA) 51) as well as MN720 are available from Seppic
(Paris, France). MN51 contains mannide oleate (MONTANIDE.RTM. 80,
also known as anhydro mannitol octadecenoate) in mineral oil
solution (Drakeol 6 VR). MONTANIDE.RTM. 80 is a limpid liquid with
a maximum acid value of 1, a saponification value of 164-172, a
hydroxyl value of 89-100, an iodine value of 67-75, a maximum
peroxide value of 2, a heavy metal value less than 20 ppm, a
maximum water content of 0.35%, a maximum color value of 9, and a
viscosity at 25.degree. C. of about 300 mPas. MONTANIDE.RTM.
associated with oil (e.g., mineral oil, vegetable oil, squalane,
squalene, or esters) is known as MONTANIDE.RTM. ISA. Drakeol 6 VR
is a pharmaceutical grade mineral oil. Drakeol 6 VR contains no
unsaturated or aromatic hydrocarbons, and has an A.P.I. gravity of
36.2-36.8, a specific gravity at 25.degree. C. of 0.834-0.838, a
viscosity at 100.degree. F. of 59-61 SSU or 10.0-10.6 centistokes,
a refractive index at 25.degree. C. of 1.458-1.463, a better than
minimum acid test, is negative for fluorescence at 360 nm, is
negative for visible suspended matter, has an ASTM pour test value
of 0-15.degree. F., has a minimum ASTM flash point of 295.degree.
F., and complies with all RN requirements for light mineral oil and
ultraviolet absorption. MN51 contains about 8 to 12 percent anhydro
mannitol octadecenoate and about 88 to 92 percent mineral oil.
[0114] Other immunostimulatory components that can be used include,
without limitation, plant extracts derived from the Soap bark tree
(Quillaja species) containing members of a family of plant-based
compounds called saponins.
[0115] Other adjuvants that can be included in a vaccine
preparation provided herein include, without limitation,
immuno-stimulating complexes (ISCOMs) that can contain such
components as cholesterol and saponins. Examples include, without
limitation, ISCOMATRIX.TM. and MATRIX-M.TM.. ISCOM matrices can be
prepared and conjugated to Cu.sup.2+. Adjuvants such as FCA, FIA,
MN51, MN720, and Al(OH).sub.3 are commercially available from
companies such as Seppic, Difco Laboratories (Detroit, Mich.), and
Superfos Biosector A/S (Vedbeak, Demark).
[0116] Other immunostimulatory components include, without
limitation, muramyldipeptide (e.g.,
N-acetylmuramyl-L-alanyl-D-isoglutamine; MDP), monophosphoryl-lipid
A (MPL), formyl-methionine containing tripeptides such as
N-formyl-Met-Leu-Phe, or a bacterial lipopolysaccharide. Such
compounds are commercially available from Sigma Chemical Co. (St.
Louis, Mo.) and RIBI ImmunoChem Research, Inc. (Hamilton, Mont.),
for example. In some cases, an adjuvant can be Complete Freund's
Adjuvant or Incomplete Freund's Adjuvant.
[0117] In some cases, a nucleic acid vaccine preparation provided
herein can be formulated to lack an adjuvant. For example, a
nucleic acid vaccine preparation provided herein can be designed to
include a nucleic acid molecule that encodes a polypeptide provided
herein without including any adjuvant.
[0118] In some cases, a polypeptide vaccine provided herein, a
nucleic acid vaccine provided herein, or a VLP vaccine provided
herein can be formulated to include other components such as
cytokines, chemokines, monoclonal antibodies, or co-stimulatory
molecules such as B7.
[0119] This document also provides methods for preparing a vaccine
preparation provided herein. Such methods can involve suspending an
amount of a polypeptide provided herein, a VLP provided herein, or
a nucleic acid vector provided herein in a suitable amount of a
physiological buffer (e.g., PBS). The polypeptides, VLPs, or
nucleic acid vectors then can optionally be combined with a
suitable amount of an adjuvant/immunostimulatory compound. The
combining step can be achieved by any appropriate method,
including, for example, stirring, shaking, vortexing, or passing
back and forth through a needle attached to a syringe.
[0120] A vaccine preparation provided herein can be prepared in
batch, such that enough unit doses are obtained for multiple
injections (e.g., injections into multiple mammals or multiple
injections into the same mammal). A "unit dose" of a vaccine
preparation provided herein refers to the amount of a vaccine
preparation administered to a mammal at one time. A unit dose of a
vaccine preparation provided herein can contain an amount of
polypeptides, VLPs, or nucleic acid molecules effective to induce
an immune response against a hepatitis B virus. For example, a unit
dose of a vaccine preparation provided herein can contain between
about 0.1 .mu.g and about 1 g (e.g., 1 .mu.g, 10 .mu.g, 15 .mu.g,
25 .mu.g, 30 .mu.g, 50 .mu.g, 100 .mu.g, 250 .mu.g, 280 .mu.g, 300
.mu.g, 500 .mu.g, 750 .mu.g, 1 mg, 10 mg, 15 mg, 25 mg, 30 mg, 50
mg, 100 mg, 250 mg, 280 mg, 300 mg, 500 mg, 750 mg, or more) of
polypeptides, VLPs, or nucleic acid molecules. In the case of
vaccine preparations containing viral vectors, a unit dose of a
vaccine preparation can have a titer between about 10.sup.3 to
10.sup.10 (e.g., 10.sup.3, 10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7,
10.sup.8, 10.sup.9, or 10.sup.10) viral particles or plaque forming
units.
[0121] This document also provides methods for inducing an immune
response within a mammal (e.g., a human) against a hepatitis B
virus. For example, one or more polypeptide vaccines provided
herein, one or more nucleic acid vaccines provided herein, one or
more VLP vaccine provided herein, or combinations thereof can be
administered to a mammal (e.g., a human) to induce an immune
response against hepatitis B viruses. In some cases, an immune
response against hepatitis B viruses can be induced by
administering one or more nucleic acid vaccines provided herein
followed by a vaccine that includes a hepatitis B virus antigen or
followed by one or more polypeptide vaccines provided herein. For
example, Vaccine ID No. 9101 can be administered to a human, and 1
to 30 days later, Vaccine ID No. 8105 can be administered to that
human. In some cases, Vaccine ID No. 9101 can be administered
followed 20 to 60 days later by Vaccine ID No. 7101. In some cases,
Vaccine ID No. 9109 can be administered followed 30 to 120 days
later by Vaccine ID No. 7106.
[0122] In some cases, a vaccine preparation provided herein can be
delivered as a prophylactic vaccine to increase a mammal's
resistance to a hepatitis B virus infection. For example, one or
more polypeptide vaccines provided herein, one or more nucleic acid
vaccines provided herein, one or more VLP vaccine provided herein,
or combinations thereof can be administered to a human who has not
been infected with a hepatitis B virus.
[0123] In some cases, a vaccine preparation provided herein can be
used to treat a mammal after the mammal is infected with hepatitis
B virus (e.g., an acutely hepatitis B virus infected or chronically
hepatitis B virus infected mammal). For example, one or more
polypeptide vaccines provided herein, one or more nucleic acid
vaccines provided herein, one or more VLP vaccine provided herein,
or combinations thereof can be administered to a human acutely or
chronically infected with hepatitis B virus. Administration of a
vaccine preparation provided herein to a mammal infected with
hepatitis B virus can result in a reduction in hepatitis B viral
load, a reduction in the severity of the symptoms of the hepatitis
B virus infection, a reduction in the degree of liver cirrhosis, a
reduction in the incidence of hepatocellular cancer, or a clearance
of the hepatitis B virus from the liver.
[0124] This document also provides methods for priming a mammal
(e.g., a human) to receive a vaccine containing a hepatitis B virus
antigen. For example, one or more polypeptide vaccines provided
herein, one or more nucleic acid vaccines provided herein, one or
more viral vaccines provided herein, one or more VLP vaccine
provided herein, or combinations thereof can be administered to a
mammal (e.g., a human) to prime that mammal for generating an
enhanced immune response against hepatitis B viruses. Once primed,
the mammal can be treated with a vaccine containing a hepatitis B
virus antigen (e.g., Engerix) or a vaccine preparation provided
herein.
[0125] A vaccine preparation provided herein can be administered
using any appropriate method. For example, the administration can
be, for example, topical (e.g., transdermal or intranasal),
pulmonary (e.g., by inhalation or insufflation of powders or
aerosols), oral, or parenteral (e.g., by intradermal, subcutaneous,
intramuscular, or intraperitoneal injection, or by intravenous
drip). Administration can be rapid (e.g., by injection) or can
occur over a period of time (e.g., by slow infusion or
administration of slow release formulations). In some cases, a
nucleic acid vaccine can be delivered intramuscularly followed 1-90
days (e.g., between 1 and 90, between 1 and 80, between 1 and 70,
between 1 and 60, between 1 and 50, between 5 and 90, between 10
and 90, between 20 and 90, between 5 and 75, between 10 and 75,
between 10 and 50, between 20 and 50, between 25 and 50, or between
30 and 60 days) later by a VLP vaccine containing adjuvant.
[0126] The invention will be further described in the following
examples, which do not limit the scope of the invention described
in the claims.
EXAMPLES
Example 1
Producing Shuffled Hepatitis B Surface Antigen
[0127] The parental DNA sequences encoding the preS2 and S regions
of the hepatitis envelope protein were derived from the human,
chimpanzee, gibbon, woolly monkey, and woodchuck hepadnaviruses and
were obtained as follows.
[0128] The preS2+S envelope sequence of the human HBV corresponding
to that of the ayw subtype (GenBank.RTM. Accession No. J02203; GI
No. 329640) was amplified by PCR from a plasmid vector called
pCAG-M-Kan. The nucleic acid sequence for this obtained DNA is set
forth in SEQ ID NO:1 and encodes a hepatitis B surface antigen
polypeptide having the amino acid sequence set forth in SEQ ID
NO:2.
[0129] The woolly monkey envelope (preS2+S) sequence (GenBank.RTM.
Accession No. AF046996; GI No. 3150070) was synthesized by
oligonucleotide gene assembly (Stemmer et al., Gene, 164(1):49-53
(1995)). The nucleic acid sequence for this obtained DNA is set
forth in SEQ ID NO:3 and encodes a hepatitis B surface antigen
polypeptide having the amino acid sequence set forth in SEQ ID
NO:4.
[0130] A hybrid envelope gene was designed by combining the preS2
sequence of the human HBV (adw2 subtype; GenBank.RTM. Accession No.
X02763; GI No. 59418) and the S sequence of the woodchuck hepatitis
virus (strain WHV8; GenBank.RTM. Accession No. J04514; GI No.
336146). The gene was synthesized by oligonucleotide gene assembly.
The nucleic acid sequence for this obtained DNA is set forth in SEQ
ID NO:5 and encodes a hepatitis B surface antigen polypeptide
having the amino acid sequence set forth in SEQ ID NO:6.
[0131] The amino acid sequence differences between the gibbon
(GenBank.RTM. Accession No. U46935; GI No. 1814218) and the
chimpanzee hepatitis (GenBank.RTM. Accession No. D00220; GI No.
163838595) preS2+S envelope proteins were minimal. A single
composite parent gene was therefore synthesized by oligonucleotide
gene assembly that contained the sum of all the amino acid changes
in the chimpanzee and gibbon sequences relative to the
corresponding human sequence. During the course of the synthesis of
this composite chimp-gibbon sequence, a mutation occurred which led
to the introduction of isoleucine at amino acid number 197 in place
of the methionine found in the wild-type chimpanzee and gibbon
sequences. The nucleic acid sequence for this obtained DNA is set
forth in SEQ ID NO:7 and encodes a hepatitis B surface antigen
polypeptide having the amino acid sequence set forth in SEQ ID
NO:8.
[0132] The workflow for the hepatitis B surface antigen (HBsAg)
library was as follows. The original library was generated using
DNAse treatment of the four parental sequences described above (SEQ
ID NOs:1, 3, 5, and 7). The shuffling of four parental sequences
was achieved by assembling DNase I-digested gene fragments.
Basically, each parental gene fragment was made from plasmids in
PCR reactions using recombinant Thermus thermophilus with two
vector primers (Pre-for-1 (+):GCA GCT CCT TGC TCC TAA CAG (SEQ ID
NO:64); and Pre-rev-2(-):GTA TCA CGA GGC CCT TTC GTC (SEQ ID
NO:65)). The PCR was performed at 30 cycles of 1 minute at
95.degree. C., 1 minute at 60.degree. C. and 2 minutes at
72.degree. C. The amplified products were purified in gel
electrophoresis and digested by DNase I into fragments ranging from
25 bp to 100 bp, which were further purified in gel. These
fragments and the three "a"-epitope constrained primers were mixed
and assembled with Taq/Pfu (9:1) polymerase in two rounds of 25
cycle PCR reactions (30 seconds at 96.degree. C., 30 seconds at
40.degree. C. and 30 seconds at 72.degree. C.). In the assembly
reactions, the percentage of "a" sequence incorporation was
controlled by adjusting the ratio of the constrained "a" oligos to
DNase I-digested gene fragments based on their molecular weights
(FIG. 1). Assembled HBs recombinants were rescued in 30 cycles of
PCR by Taq polymerase (Qiagen) with two nested primers (V1521+: GCT
GAC AGA CTA ACA GAC TG (SEQ ID NO:66); and V2453 (-): AAC AGA TGG
CTG GCA ACT AG (SEQ ID NO:67); 30 seconds at 95.degree. C., 30
seconds at 55.degree. C., and 1 minute at 72.degree. C.).
Subsequently, the shuffled HBs fragments were digested with EcoR
I/Asp718, purified in gel, and cloned into EcoR I/Asp718-cut pMKan
vector using a standard cloning procedure.
[0133] The HBs "a" loop is a major neutralizing epitope and induces
protective neutralizing antibodies against hepatitis B virus
infection. To preserve this sequence, "a" epitope-constrained
libraries were generated. In the assembly reactions, the individual
"a" epitope-constrained primer was mixed with the DNase I-digested
parental HBs fragments at three concentrations, 0.5:1, 1:1, and
2:1. The incorporation of `a` epitope primers in shuffling
reactions were identified by BsrB I restriction enzyme digestion of
the assembled HBs fragments. The rate was further evaluated with
BsrB I-digested plasmid DNA samples. The ratio of 0.5:1 exhibited
about 30% incorporation, and both 1:1 and 2:1 ratios exhibited
60-65% incorporation. Sequencing analyses of plasmid clones
indicated that the three constrained `a` epitopes were equally
incorporated.
`a` Loop-Constrained Primers
[0134] The thirty nucleotides of the human `a` loop 1 sequence were
held constant and flanked by fifteen nucleotides on each side
derived from the related HBs genes of Chimpanzee/Gibbon (chibbon),
Woolly Monkey (WM), or Woodchuck (WD) (FIG. 2). The primers were
designed for human HBs `a` constrained epitopes in the
chimpanzee/gibbon hybrid (SEQ ID NO:7), Woolly monkey (SEQ ID
NO:3), and human/woodchuck hybrid (SEQ ID NO:5).
Screening
[0135] Clones from the library were screened for protein expression
using an immunofluorescence assay (IFA) for expression. Briefly,
DNA prepared by BioRobot 9600 was transfected to Cos-7 cells (ATCC
#CRL-1651) using SuperFect.TM. transfection reagent in 96-well
format as described by the manufacturer (Qiagen). At 48-hour
post-transfection, the cells were fixed with paraformaldehyde and
stained with goat anti-HBs antibody (Dako #B0560), and then
FITC-conjugated rabbit anti-goat immunoglobulins (Dako #PO449). The
FITC-positive cells were visualized under fluorescent microscopy.
Clones that produced positive IFA signals were then screened in
mice by direct intramuscular injection of the plasmid DNA,
injecting one shuffled clone in a single mouse. Antibody responses
were measured using validated clinical kits (either the Monolisa
anti-HBs 3.0 ELISA from Sanofi Diagnostics or the AUSAB EIA ELISA
from Abbott Laboratories) and by standard ELISA assays using
commercial preparations of the HBsAg obtained from (Seradyn
recombinant HBsAg #ABH0705) or the wild-type ayw or adw2 preS2
peptides (custom synthesized by Seradyn) (FIG. 3).
[0136] The most immunogenic clones were further analyzed in larger
groups of mice (FIG. 37). Briefly, purified DNA (Aldevron LLC,
Fargo, N. Dak.) was diluted to a final concentration of 100
.mu.g/mL in sterile PBS. For each test group, 10 six-week old
C57BL/6 mice were injected intramuscularly with 50 .mu.L DNA
solution in the tibialis anterior muscle of each leg muscle (10
.mu.g DNA total per mouse). Sera were analyzed 4 weeks after
treatment for the level of anti-HBsAg as measured by the Sanofi
Monolisa anti-HBS kit (expressed above as the GMT.+-.SEM for each
group in mIU per mL). Titers were calculated for mice that received
clones 6101, 6102, 6103, 6104, 6105, 6106, 6107, 6108, 6109, or
6111, or the wild-type human hepatitis B envelope gene (HBV). Mice
injected with clones 6103, 6104, 6105, 6107, or 6111 from the first
round library developed titers that were significantly higher than
those in mice that were injected with the wild-type hepatitis B
envelope gene containing plasmid control (HBV) (FIG. 37).
[0137] Based on these results, ten clones were selected (clones
6101, 6102, 6103, 6104, 6105, 6106, 6107, 6108, 6109, and 6111) and
then shuffled to generate a second round library. This library was
screened as before (IFA and mouse immunization), and immunogenic
clones were selected and analyzed further in larger groups of
animals (FIG. 39). Briefly, purified DNA (Aldevron LLC, Fargo, N.
Dak.) was diluted to a final concentration of 100 .mu.g/mL in
sterile PBS. For each test group, 10 six-week old C57BL/6 mice were
anesthetized and injected intramuscularly with 50 .mu.L DNA
solution in the tibialis anterior muscle of each leg muscle (10
.mu.g DNA total per mouse). Sera was analyzed 4 weeks after
treatment for the level of anti-hepatitis B antibody as measured by
the Sanofi Monolisa anti-HBS kit (expressed above as the GMT.+-.SEM
for each group in International Units). Titers were calculated for
mice that received clones 6201, 6202, 6204, 6205, 6208, 6209, 6210,
6212, 6213, or 6215, or the wild-type human hepatitis B envelope
gene (HBV). Mice injected with clones 6201, 6202, 6204, 6205, 6208,
6209, 6210, 6212, 6213, or 6215 developed titers that were
significantly higher than those in mice that were injected with the
wild-type hepatitis B envelope gene containing plasmid control
(HBV) (FIG. 38).
[0138] The nucleic acid and amino acid sequences of the original
four parents (FIGS. 4-7), the ten clones selected from the first
round of shuffling (FIGS. 8-17), and the fifteen clones selected
from the second round of shuffling (FIGS. 18-32) are presented in
FIGS. 4-32. An alignment of the parental and shuffled DNA and
protein sequences were obtained using the Clustal W algorithm
within the AlignX component of Vector NTI ver 6.0 and are shown in
FIGS. 33 and 34, respectively. A summary of the amino acid changes
for the clones shown in FIGS. 8-32 is shown in FIG. 35, along with
an indication of the various regions of the protein. The nucleotide
sequence and component locations of the vector used in this work
are shown in FIG. 36.
[0139] All but two of the clones (clones 6101 and 6111) were
obtained from a shuffled library in which the main antigenic
determinant (the so-called "a-loop") of the human HBV envelope
protein was held constant during the shuffling reaction. This was
accomplished by including specific oligonucleotides in the
shuffling reaction to generate clones in which this sequence was
held constant. Several obtained clones did not retain this
conserved a-loop in its entirety due to a spontaneous mutation not
found in any of the parents used in the shuffling reaction (proline
at amino acid number 183 in the place of alanine in the wild-type
sequence).
[0140] To obtain additional reliable data, an experiment was
conducted in which three first round clones (6104, 6105, and 6108)
and five second round clones (6202, 6204, 6205, 6212, and 6215)
were used to immunize groups of 30 mice per clone. In this
experiment, four plasmids were used that express each of the
parental envelope sequences used in the initial shuffling reaction
(designated HBV, WM, CH, and WD in FIG. 39). Briefly, purified DNA
(Aldevron LLC, Fargo, N. Dak.) was diluted to a final concentration
of 100 .mu.g/mL in sterile PBS. For each test group, 30 six-week
old C57BL/6 mice were anesthetized and injected intramuscularly
with 50 .mu.L DNA solution in the tibialis anterior muscle of each
leg muscle (10 .mu.g DNA total per mouse). Sera were analyzed four
weeks after treatment for the level of anti-hepatitis B antibody as
measured by the Abbott AUSZYME ELISA (expressed above as the
GMT.+-.SEM for each group in International Units). Titers were
calculated for mice that received DNA clones from the first round
library (6104, 6105, and 6108), the second round library (6202,
6204, 6205, 6212, and 6215), and the parents from the original
shuffling reaction (wild-type human hepatitis B envelope gene
(HBV), woolly monkey hepatitis envelope gene (WM),
chimpanzee/gibbon hepatitis envelope gene (CH), and woodchuck
hepatitis envelope (WD)). Another group of mice were injected with
1 .mu.g of the commercially available hepatitis B recombinant
protein vaccine (Engerix-B, SmithKline Beecham), which was derived
from a wild-type HBV gene sequence.
[0141] Mice injected with clones 6104, 6105, 6108, 6202, 6204,
6205, 6212, and 6215 developed titers that were significantly
higher than mice that were injected with the original parental
clones including the wild-type Hepatitis B envelope gene containing
plasmid control (HBV) (FIG. 39). The commercial protein vaccine
containing purified protein from the wild-type human Hepatitis B
envelope gene adjuvanted with aluminum elicited a superior titer
compared to DNA injection of the gene by itself (compare "Engerix"
to "HBV"). The titer obtained with the commercial vaccine (Engerix)
was surpassed by clones 6104, 6105, 6202, 6204, 6205, 6212, and
6215.
[0142] Clones 6104, 6105, 6108, 6202, 6204, 6205, 6212, and 6215
were further analyzed for their ability to prime the immune system
to respond to wild-type hepatitis B surface antigen. Briefly,
purified DNA (Aldevron LLC, Fargo, N. Dak.) was diluted to a final
concentration of 100 .mu.g/mL in sterile PBS. For each test group,
20 six-week old C57BL/6 mice were anesthetized and injected
intramuscularly with 50 .mu.L DNA solution in the tibialis anterior
muscle of each leg muscle (10 .mu.g DNA total per mouse). Three
weeks after the initial DNA immunization, 10 mice in each group
were injected intraperitoneally with 1 .mu.g of the commercially
available hepatitis B recombinant protein vaccine (Engerix-B,
SmithKline Beecham) diluted four fold in endotoxin free PBS (5
.mu.g/mL final). Two weeks after the protein injection sera from
all mice was analyzed for the level of anti-hepatitis B antibody as
measured by the Abbott AUSZYME ELISA (expressed above as the GMT
for each group in International Units). Titers were calculated for
mice that received DNA clones 6104, 6105, 6108, 6202, 6204, 6205,
6212, or 6215, one of the four parental clones, or the backbone DNA
plasmid containing an irrelevant gene sequence.
[0143] Clones 6202, 6204, 6205, 6212, and 6215 were superior to the
wild-type hepatitis B envelope protein gene for priming the immune
system to respond to the hepatitis B protein (FIG. 40). This
improved priming was exemplified by the significantly larger memory
responses observed after the protein injection in mice that
received the shuffled clones as compared to mice that received the
wild-type clone (compare black bars of 6104, 6105, 6108, 6202,
6204, 6205, 6212, and 6215 with black bar of HBV in FIG. 40). The
relative titers between groups that only received the DNA prime
(grey bars) were very similar to the relationships seen in previous
experiments (see FIG. 37), but the post boost titers did not
maintain this relationship. This change of profile indicated that
the high memory response was not solely due to a simple boosting of
the higher titer produced by primary injection but rather may
indicate that there are aspects of the shuffled genes that enable
them to enhance the immune system's ability to respond to a second
exposure (compare grey and black bars of 6202 to those of
6205).
[0144] In another experiment, clones 6102, 6103, 6104, 6105, 6108,
6205, 6212, and 6213 were tested in a population of outbred mice.
Briefly, purified DNA (Aldevron LLC, Fargo, N. Dak.) was diluted to
a final concentration of 1000 .mu.g/mL in sterile PBS. For each
test group, 10 six-week old outbred Swiss Webster mice were
anesthetized and injected intramuscularly with 50 .mu.L DNA
solution in the tibialis anterior muscle of each leg muscle (100
.mu.g DNA total per mouse). Sera were analyzed four weeks after
treatment for the level of anti-hepatitis B antibody as measured by
Abbott AUSZYME ELISA. Titers were calculated for groups of ten mice
each that received clones 6102, 6103, 6104, 6105, 6108, 6205, 6212,
or 6213, or for two groups of ten mice each that received the
wild-type human hepatitis B envelope gene (HBV). Groups of mice
injected with clones 6103, 6105, 6108, 6205, 6212, and 6213
exhibited a higher percentage of seroconverting mice and/or higher
anti-HBsAg titers than groups of mice that were injected with the
wild-type hepatitis B envelope gene containing plasmid control
(HBV) (FIG. 41). This population of outbred mice more accurately
reflects the heterogeneity seen in natural populations. The ability
of shuffled clones to outperform the wild-type clone in this
environment suggests that the shuffled clones may outperform the
wild-type sequences in other outbred populations such as the human
population.
[0145] In another experiment, clones 6104 and 6105 were tested in a
population of non-responder mice. Briefly, purified DNA (Aldevron
LLC, Fargo, N. Dak.) was diluted to a final concentration of 1000
.mu.g/mL in sterile PBS. For each test group, 10 six-week old B10M
mice were anesthetized and injected intramuscularly with 50 .mu.L
DNA solution in the tibialis anterior muscle of each leg muscle
(100 .mu.g DNA total per mouse). Sera were collected by
retro-orbital methods four weeks after treatment, and the mice were
then given a second dose of DNA. Three weeks after the second
treatment, sera was collected. The level of anti-hepatitis B
antibody as measured by the Abbott AUSZYME ELISA (expressed as the
GMT.+-.SEM for each group in International Units) was determined
for both the sera after a single treatment (grey bars in FIG. 42)
and the sera after two doses (black bars in FIG. 42). Titers were
calculated for mice that received DNA clones 6104 and 6105 and
wild-type human hepatitis B envelope gene (HBV) (FIG. 42).
[0146] Shuffled clones 6104 and 6105 were able to stimulate strong
immune responses in a mouse strain that typically does not respond
to hepatitis B antigens. These results were particularly
interesting because the B10.M non-responder strain of mice may be
similar to a subset of chronically infected humans who also do not
respond to HBsAg. The ability of the shuffled clones to overcome
this lack of response demonstrates that the shuffled clones
provided herein can be used as a therapeutic against chronic
hepatitis B.
Other Embodiments
[0147] It is to be understood that while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. Other aspects, advantages, and modifications are
within the scope of the following claims.
Sequence CWU 1
1
691846DNAArtificial Sequencesynthetic nucleic acid 1atgcagtgga
attccacaac cttccaccaa actctgcaag atcccagagt gagaggcctg 60tatttccctg
ctggtggctc cagttcagga acagtaaacc ctgttctgac tactgcctct
120cccttatcgt caatcttctc gaggattggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cgcagagtct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgtgtc ttggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcaagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accagcacgg
gaccatgccg gacctgcatg 540actactgctc aaggaacctc tatgtatccc
tcctgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgtttggct ttcagttata tggatgatgt ggtattgggg
gccaagtctg 780tacagcatct tgagtccctt tttaccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 8462281PRTArtificial
Sequencesynthetic polypeptide 2Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Phe Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Val Leu Thr
Thr Ala Ser Pro Leu Ser Ser Ile Phe Ser Arg 35 40 45 Ile Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Leu Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Arg Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Met Met Trp Tyr Trp 245 250 255 Gly Pro Ser Leu Tyr Ser Ile Leu Ser
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 3852DNAArtificial Sequencesynthetic nucleic acid
3atgcagtgga attccacttc cttccagagt tatcttcaga atccaaaggt cagaggcctc
60tactttcctg ctggtggctc aacttcaagc attgtcaacc ctgttccgac cactgcctcc
120accacatcgt caagcttctc gacgactggg gtccctgtca gcaccatgga
catcacttca 180tcaggattcc taggacccct tctcgcatta caggcggtgt
ttttcttgtt gacaaaaatc 240ctcacaatgc cacagagtct agactcgttg
tggacttctc tcaattttct agggggaaca 300ccagcgtgtc ctggcctaaa
ttcgcagtcc ccaacctcca gtcactcacc aacctgctgt 360ccaccgactt
gtcctgggta tcgctggatg tgtttgcggc gttctatcat cttcctcttc
420atcctgcttc tatgcctcat cttcttgttg gttcttctgg actaccaagg
tatgttgccc 480gtgtgtcctc ttctaccaac agttacagga acaacaacaa
caacgggacc ctgcaggacc 540tgcacgccaa ttgttccagg catctcttcg
tatccctcat gttgctgtac caaacctacg 600gacggaaact gcacttgtat
tcccatcccc tcatcatggg ctttcgcaaa gttcctatgg 660gactgggcct
tagcccgttt ctcctggctc aattcacttc tgccatttgt tcagtggttc
720gcagggcttt cccccactgt atggctttta gttatatgga tgatgtggtt
ctgggggcca 780agtctgttca gcatcttgag tcccttcttg cctctgttac
cacttttctt ttggctttgg 840gtatacattt aa 8524283PRTArtificial
Sequencesynthetic polypeptide 4Met Gln Trp Asn Ser Thr Ser Phe Gln
Ser Tyr Leu Gln Asn Pro Lys1 5 10 15 Val Arg Gly Leu Tyr Phe Pro
Ala Gly Gly Ser Thr Ser Ser Ile Val 20 25 30 Asn Pro Val Pro Thr
Thr Ala Ser Thr Thr Ser Ser Ser Phe Ser Thr 35 40 45 Thr Gly Val
Pro Val Ser Thr Met Asp Ile Thr Ser Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Ala Leu Gln Ala Val Phe Phe Leu Leu Thr Lys Ile65 70 75
80 Leu Thr Met Pro Gln Ser Leu Asp Ser Leu Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Pro Ala Cys Pro Gly Leu Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Ser His Ser Pro Thr Cys Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Ser Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Leu
Pro Thr Val Thr Gly Thr Thr Thr Thr Thr Gly 165 170 175 Pro Cys Arg
Thr Cys Thr Pro Ile Val Pro Gly Ile Ser Ser Tyr Pro 180 185 190 Ser
Cys Cys Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys Ile Pro 195 200
205 Ile Pro Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Asp Trp Ala Leu
210 215 220 Ala Arg Phe Ser Trp Leu Asn Ser Leu Leu Pro Phe Val Gln
Trp Phe225 230 235 240 Ala Gly Leu Ser Pro Thr Val Trp Leu Leu Val
Ile Trp Met Met Trp 245 250 255 Phe Trp Gly Pro Ser Leu Phe Ser Ile
Leu Ser Pro Phe Leu Pro Leu 260 265 270 Leu Pro Leu Phe Phe Trp Leu
Trp Val Tyr Ile 275 280 5834DNAArtificial Sequencesynthetic nucleic
acid 5atgcagtgga attccactgc cttccaccaa actctgcagg atcccagagt
caggggtctg 60tatcttcctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa
tattgcctct 120cacatctcgt caatctccgc gaggactggg gaccctgtga
cgaacatgtc accatcaagt 180ctcctaggac tcctcgcagg attacaggtg
gtgtatttct tgtggacaaa aatcctaaca 240atagctcaga atctagattg
gtggtggact tctctcagtt ttccaggggg cataccagag 300tgcactggcc
aaaattcgca gttccaaact tgcaaacact tgccaacctc ctgtccacca
360acttgcaatg gctttcgttg gatgtatctg cggcgtttta tcatatacct
attagtcctg 420ctgctgtgcc tcatcttctt gttggttctc ctggactgga
aaggtttaat acctgtctgt 480cctcttcaac ccacaacaga aacaacagtc
aattgcagac aatgcacaat ctctgcacaa 540gacatgtata ctcctcctta
ctgttgttgt ttaaaaccta cggcaggaaa ttgcacttgt 600tggcccatcc
cttcatcatg ggctttagga aattacctat gggagtgggc cttagcccgt
660ttctcttggc tcaatttact agtgcccttg cttcaatggt taggaggaat
ttccctcatt 720gcgtggtttt tgcttatatg gatgatttgg ttttgggggc
ccgcacttct gagcatctta 780ccgccattta ttcccatatt tgttctgttt
ttcttgattt gggtatacat ttaa 8346277PRTArtificial Sequencesynthetic
polypeptide 6Met Gln Trp Asn Ser Thr Ala Phe His Gln Thr Leu Gln
Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser
Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn Ile Ala Ser His
Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp Pro Val Thr Asn
Met Ser Pro Ser Ser Leu Leu Gly Leu 50 55 60 Leu Ala Gly Leu Gln
Val Val Tyr Phe Leu Trp Thr Lys Ile Leu Thr65 70 75 80 Ile Ala Gln
Asn Leu Asp Trp Trp Trp Thr Ser Leu Ser Phe Pro Gly 85 90 95 Gly
Ile Pro Glu Cys Thr Gly Gln Asn Ser Gln Phe Gln Thr Cys Lys 100 105
110 His Leu Pro Thr Ser Cys Pro Pro Thr Cys Asn Gly Phe Arg Trp Met
115 120 125 Tyr Leu Arg Arg Phe Ile Ile Tyr Leu Leu Val Leu Leu Leu
Cys Leu 130 135 140 Ile Phe Leu Leu Val Leu Leu Asp Trp Lys Gly Leu
Ile Pro Val Cys145 150 155 160 Pro Leu Gln Pro Thr Thr Glu Thr Thr
Val Asn Cys Arg Gln Cys Thr 165 170 175 Ile Ser Ala Gln Asp Met Tyr
Thr Pro Pro Tyr Cys Cys Cys Leu Lys 180 185 190 Pro Thr Ala Gly Asn
Cys Thr Cys Trp Pro Ile Pro Ser Ser Trp Ala 195 200 205 Leu Gly Asn
Tyr Leu Trp Glu Trp Ala Leu Ala Arg Phe Ser Trp Leu 210 215 220 Asn
Leu Leu Val Pro Leu Leu Gln Trp Leu Gly Gly Ile Ser Leu Ile225 230
235 240 Ala Trp Phe Leu Leu Ile Trp Met Ile Trp Phe Trp Gly Pro Ala
Leu 245 250 255 Leu Ser Ile Leu Pro Pro Phe Ile Pro Ile Phe Val Leu
Phe Phe Leu 260 265 270 Ile Trp Val Tyr Ile 275 7846DNAArtificial
Sequencesynthetic nucleic acid 7atgcagtgga attctacagt attccaccaa
gctctgcaag atcccagagt acggggccta 60tactttcctg ttggtggctc cagttcagga
acattgaacc ctgttccgaa tactgcctct 120cacatctcgt cagtcttctc
gacgactggg gaccctgcac cgaacatgga gaacatcaca 180tcaggattcc
taggacccct gctcgtgtta caggcggggt ttttcttgtt gacaaaaatc
240ctcacaatac cacagagtct agactcgtgg tggacttctc tcaattttct
agggggagca 300cccgtgtgtc ctggccaaaa ttcgcagtcc ccaacctcca
atcactcacc aacctcttgt 360cctccaattt gtcctggcta tcgctggatg
tgtctgcggc gttttatcat cttcctcttc 420atcctgctgc tatgcctcat
cttcttgttg gttcttctgg actatcaagg tatgttgccc 480gtttgtcctc
tacttccagg atcatcgacc accagcacgg gaccatgcaa aacctgcacg
540atccctgctc aaggaacctc tttgattccc tcatgttgtt gtacaaaacc
ttcggacgga 600aattgcactt gtattcccat cccatcgtct tgggctttcg
caaaattcct atgggagtgg 660gcctcagtcc gtttctcctg gctcagttta
ctagctccat ttgttcagtg gttcgcaggg 720ctttccccca ctgcttggct
tttagctata tggatcatct ggtattgggg gccaaatctg 780tacaacatct
tgaatccatt tataccgctg ttaccaattt tcttttgtct ttgggtatac 840atttaa
8468281PRTArtificial Sequencesynthetic polypeptide 8Met Gln Trp Asn
Ser Thr Val Phe His Gln Ala Leu Gln Asp Pro Arg1 5 10 15 Val Arg
Gly Leu Tyr Phe Pro Val Gly Gly Ser Ser Ser Gly Thr Leu 20 25 30
Asn Pro Val Pro Asn Thr Ala Ser His Ile Ser Ser Val Phe Ser Thr 35
40 45 Thr Gly Asp Pro Ala Pro Asn Met Glu Asn Ile Thr Ser Gly Phe
Leu 50 55 60 Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu
Thr Lys Ile65 70 75 80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp
Thr Ser Leu Asn Phe 85 90 95 Leu Gly Gly Ala Pro Val Cys Pro Gly
Gln Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser
Cys Pro Pro Ile Cys Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg
Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile
Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160
Val Cys Pro Leu Leu Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165
170 175 Lys Thr Cys Thr Ile Pro Ala Gln Gly Thr Ser Leu Ile Pro Ser
Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile
Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu
Trp Ala Ser Val Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Ala Pro
Phe Val Gln Trp Phe Ala Gly225 230 235 240 Leu Ser Pro Thr Ala Trp
Leu Leu Ala Ile Trp Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu
Tyr Asn Ile Leu Asn Pro Phe Ile Pro Leu Leu Pro 260 265 270 Ile Phe
Phe Cys Leu Trp Val Tyr Ile 275 280 9864DNAArtificial
Sequencesynthetic nucleic acid 9atgcagtgga attctacagt attccaccaa
actctgcaag atcccagagt ggggggtctg 60tatcttcctg ctggtggctc cagttcagga
acagtaaacc ctgttctgac tactgcctct 120cccttatcgt caatcttctc
gaggattggg gaccctgcgc tgaacatgga gaacatcaca 180tcaggattcc
taggacccct tctcgtgtta caggcggggt ttttcttgat gacaaaaatc
240ctcacaatgc cgcagagtct agactcgtgg tggacttctc tcaattttct
agggagagca 300cccgtgtgtc ctggccaaaa ttcgcagtcc ccaacctcca
atcactcacc aacctcttgt 360cctccaattt gtcctggcta tcgctggatg
tgtctgcggc gttttatcat cttcctcttc 420atcctgctgc tatgcctcat
cttcttgttg gttcttctgg actatcgagg tatgttgccc 480gtttgtcctc
tacttccagg atcatcgacc accagcacgg gaccatgcaa aacctgcacg
540atccctgctc aaggaacctc tttgattccc tcatgttgtt gtacaaaacc
ttcggacgga 600aattgcactt gtattcccat cccatcgtct tgggctttcg
caaaattcct atgggagtgg 660gcctcagtcc gtttctcctg gctcagttta
ctagctccat ttgttcagcg gttcgcaggg 720ctttccccca ctgcttggct
tttagctata tggatcatct ggtattgggg gccaaatctg 780tacaacatct
tgagtccctt cttgccgctg ttaccaattt tcttttgtct ttgggtatac
840atttaaatgc tagaggtacc ctga 86410281PRTArtificial
Sequencesynthetic polypeptide 10Met Gln Trp Asn Ser Thr Val Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Gly Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Val Leu Thr
Thr Ala Ser Pro Leu Ser Ser Ile Phe Ser Arg 35 40 45 Ile Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Met Thr Lys Ile65 70 75
80 Leu Thr Met Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Arg Ala Pro Val Cys Pro Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Leu
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Thr Ile Pro Ala Gln Gly Thr Ser Leu Ile Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu Trp Ala Ser Val Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Ala Pro Phe Val Gln Arg Phe
Ala Gly225 230 235 240 Leu Ser Pro Thr Ala Trp Leu Leu Ala Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Ser
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 11846DNAArtificial Sequencesynthetic nucleic acid
11atgcagtgga attccacaac cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa tactgcctct
120cacatctcgt cagtcttctc gacgactggg gaccctgcac cgaacatgga
gaacatcaca 180tcaggattcc taggacccct gctcgtgtta caggcggggt
ttttcttgtt gacaaaaatc 240ctcacaatgc cacagagtct agactcgttg
tggacttctc tcaattttct agggggaaca 300ccagcgtgtc ttggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accagcacgg
gaccttgcag gacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgtt gtacaaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggactgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagcg gttcgcaggg
720ctttctccca ctgcttggct ttcagttata tggatgatgt ggtattgggg
accaagtctg 780tacagcatct tgagtccctt tttaccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84612281PRTArtificial
Sequencesynthetic polypeptide 12Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5
10 15 Val Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser Ser Ser Gly Thr
Val 20 25 30 Asn Pro Ala Pro Asn Thr Ala Ser His Ile Ser Ser Val
Phe Ser Thr 35 40 45 Thr Gly Asp Pro Ala Pro Asn Met Glu Asn Ile
Thr Ser Gly Phe Leu 50 55 60 Gly Pro Leu Leu Val Leu Gln Ala Gly
Phe Phe Leu Leu Thr Lys Ile65 70 75 80 Leu Thr Met Pro Gln Ser Leu
Asp Ser Leu Trp Thr Ser Leu Asn Phe 85 90 95 Leu Gly Gly Thr Pro
Ala Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His
Ser Pro Thr Ser Cys Pro Pro Thr Cys Pro Gly Tyr Arg 115 120 125 Trp
Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135
140 Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met Leu
Pro145 150 155 160 Val Cys Pro Leu Ile Pro Gly Ser Ser Thr Thr Ser
Thr Gly Pro Cys 165 170 175 Arg Thr Cys Met Thr Thr Ala Gln Gly Thr
Ser Met Tyr Pro Ser Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly
Asn Cys Thr Cys Ile Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Gly
Lys Phe Leu Trp Asp Trp Ala Ser Ala Arg 210 215 220 Phe Ser Trp Leu
Ser Leu Leu Val Pro Phe Val Gln Arg Phe Ala Gly225 230 235 240 Leu
Ser Pro Thr Ala Trp Leu Ser Val Ile Trp Met Met Trp Tyr Trp 245 250
255 Gly Pro Ser Leu Tyr Ser Ile Leu Ser Pro Phe Leu Pro Leu Leu Pro
260 265 270 Ile Phe Phe Cys Leu Trp Val Tyr Ile 275 280
13846DNAArtificial Sequencesynthetic nucleic acid 13atgcagtgga
attccactgc cttccaccaa actctgcagg atcccagagt caggggtctg 60tatctccctg
ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggactggg gaccctgcac cgaacatgga
gaacatcaca 180tcaggattcc taggacccct gctcgtgtta caggcggtgt
ttttcttgtt gacaagaatc 240ctcacaatac cgcagagtct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgtgtc ctggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat atacctatta
420gtcctgctgc tgtgcctcat cttcttgttg gttcttctgg actatcaagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accagcacgg
gaccatgcaa aacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgtt gtacaaaacc ttcggacgga 600aattgcactt gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagcg gttcgcaggg
720ctttccccca ctgtttggct ttcagttata tggatgattt ggttttgggg
gccaagtctg 780tacagcatct tgagtccctt tttaccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84614281PRTArtificial
Sequencesynthetic polypeptide 14Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp
Pro Ala Pro Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Val Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Pro Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Tyr
Leu Leu Val Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Arg Phe
Ala Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Met Ile Trp Phe Trp 245 250 255 Gly Pro Ser Leu Tyr Ser Ile Leu Ser
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 15846DNAArtificial Sequencesynthetic nucleic acid
15atgcagtgga attctacaac cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggactggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cacagagtct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgtgtc ttggcctaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgcttc tatgcctcat cttcttgttg gttcttctgg actatcaagg
tatgttgccc 480gtttgtcccc taattccagg atcctcaaca accagcacgg
gaccatgcaa aacctgtatg 540actacccctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgcttggct tttggctata tggatcatct ggtattgggg
gccaaatctg 780tacaacatct tgaatccctt tttaccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84616281PRTArtificial
Sequencesynthetic polypeptide 16Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Leu Gly Leu Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Pro Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Ala Trp Leu Leu Ala Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 17846DNAArtificial Sequencesynthetic nucleic acid
17atgcagtgga attccactgc cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagctcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggattggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgcatta caggcggtgt
ttttcttgtt gacaaaaatc 240ctcacaatgc cacagagtct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgtgtc ttggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accagcacgg
gaccatgcaa aacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgtt gtacaaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg caaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgtttggct ttcagttata tggatgatgt ggtattgggg
gccaagtctg 780ttcagcatct tgagtccctt cttgcctctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84618281PRTArtificial
Sequencesynthetic polypeptide 18Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Ile Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Ala Leu Gln Ala Val Phe Phe Leu Leu Thr Lys Ile65 70 75
80 Leu Thr Met Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Leu Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Met Met Trp Tyr Trp 245 250 255 Gly Pro Ser Leu Phe Ser Ile Leu Ser
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 19846DNAArtificial Sequencesynthetic nucleic acid
19atgcagtgga attccacaac cttccaccaa actctgcaag atcccagagt gagaggcctg
60tatttccctg ctggtggctc cagttcagga acagtaaacc ctgttctgac tactgcctct
120cccttatcgt caatcttctc gaggattggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cgcagagtct agactcgttg
tggacttctc tcagttttcc agggggcata 300ccagagtgca ctggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc tacttccagg atcctcaaca accagcacgg
gaccctgcag gacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg caaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgtttggct ttcagttata tggatcatct ggtattgggg
gccaaatctg 780tacaacatct tgaatccatt tataccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84620281PRTArtificial
Sequencesynthetic polypeptide 20Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Phe Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Val Leu Thr
Thr Ala Ser Pro Leu Ser Ser Ile Phe Ser Arg 35 40 45 Ile Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Leu Trp Thr Ser Leu Ser Phe
85 90 95 Pro Gly Gly Ile Pro Glu Cys Thr Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Leu
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Arg Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Ile Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 21846DNAArtificial Sequencesynthetic nucleic acid
21atgcagtgga attccactgc cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cccttatcgt caatcttctc gacgactggg gaccctgcac cgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cgcagagtct agactcgtgg
tggacttctc tcaattttct agggggagca 300cccgtgtgtc ttggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctgggta tcgctggatg cgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accggcacgg
gaccctgcag gacctgtatg 540actactgctc aaggaacctc tatgtatccc
tcatgttgtt gtacaaaacc ttcggacgga 600aattgcactt gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttcccccg ctgtatggct ttcagttata tggatgatgt ggtattgggg
gccaagtctg 780tacagcatct tgagtccctt tttaccgctg ttaccaattt
tcttttggct ttgggtatac 840atttaa 84622281PRTArtificial
Sequencesynthetic polypeptide 22Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser Pro Leu Ser Ser Ile Phe Ser Thr 35 40 45 Thr Gly Asp
Pro Ala Pro Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Ala Pro Val Cys Leu Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Arg Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155
160 Val Cys Pro Leu Ile Pro Gly Ser Ser Thr Thr Gly Thr Gly Pro Cys
165 170 175 Arg Thr Cys Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro
Ser Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys
Ile Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp
Glu Trp Ala Ser Ala Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Val
Pro Phe Val Gln Trp Phe Val Gly225 230 235 240 Leu Ser Pro Ala Val
Trp Leu Ser Val Ile Trp Met Met Trp Tyr Trp 245 250 255 Gly Pro Ser
Leu Tyr Ser Ile Leu Ser Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile
Phe Phe Trp Leu Trp Val Tyr Ile 275 280 23840DNAArtificial
Sequencesynthetic nucleic acid 23atgcagtgga attctactgc cttccaccaa
actctgcagg atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagttcagga
acagtaaacc ctgctccgaa tattgcctct 120cacatctcgt caatctccgc
gaggactggg gaccctgtga cgaacatgtc accatcaagt 180ctcctaggac
tcctcgcagg attacaggtg gtgtatttct tgtggacaaa aatcctaaca
240ataccgcaga gtctagactc gtggtggact tctctcaatt ttctaggggg
agcacccgtg 300tgtcctggcc aaaattcgca gtccccaacc tccaatcact
caccaacctc ttgtcctcca 360atttgtcctg gttatcgctg gatgtgtctg
cggcgtttta tcatcttcct cttcatcctg 420cttctatgcc tcatcttctt
gttggttctt ctggactatc aaggtatgtt gcccgtttgt 480cctctaattc
caggatcatc gaccaccagc acgggaccat gcaaaacctg tatgactacc
540cctcaaggaa cctctatgta tccctcatgt tgttgtacca aaccttcgga
cggaaattgc 600acctgtattc ccatcccatc atcctgggct ttcggaaaat
tcctatggga gtgggcctca 660gtccgtttct cctggctcag tttactagct
ccatttgttc agcggttcgt agggctttcc 720cccactgttt ggctttcagt
tatatggatg atgtggttct gggggccaag tctgttcagc 780atcttgagtc
ccttcttgcc tctgttacca cttttctttt ggctttgggt atacatttaa
84024279PRTArtificial Sequencesynthetic polypeptide 24Met Gln Trp
Asn Ser Thr Ala Phe His Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val
Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25
30 Asn Pro Ala Pro Asn Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg
35 40 45 Thr Gly Asp Pro Val Thr Asn Met Ser Pro Ser Ser Leu Leu
Gly Leu 50 55 60 Leu Ala Gly Leu Gln Val Val Tyr Phe Leu Trp Thr
Lys Ile Leu Thr65 70 75 80 Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr
Ser Leu Asn Phe Leu Gly 85 90 95 Gly Ala Pro Val Cys Pro Gly Gln
Asn Ser Gln Ser Pro Thr Ser Asn 100 105 110 His Ser Pro Thr Ser Cys
Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met 115 120 125 Cys Leu Arg Arg
Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu 130 135 140 Ile Phe
Leu Leu Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys145 150 155
160 Pro Leu Ile Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys Lys Thr
165 170 175 Cys Met Thr Thr Pro Gln Gly Thr Ser Met Tyr Pro Ser Cys
Cys Cys 180 185 190 Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro
Ile Pro Ser Ser 195 200 205 Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp
Ala Ser Val Arg Phe Ser 210 215 220 Trp Leu Ser Leu Leu Ala Pro Phe
Val Gln Arg Phe Val Gly Leu Ser225 230 235 240 Pro Thr Val Trp Leu
Ser Val Ile Trp Met Met Trp Phe Trp Gly Pro 245 250 255 Ser Leu Phe
Ser Ile Leu Ser Pro Phe Leu Pro Leu Leu Pro Leu Phe 260 265 270 Phe
Trp Leu Trp Val Tyr Ile 275 25840DNAArtificial Sequencesynthetic
nucleic acid 25atgcagtgga attctactgc cttccaccaa actctgcagg
atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagttcagga acagtaaacc
ctgctccgaa tattgcctct 120cacatctcgt caatctccgc gaggactggg
gaccctgtga cgaacatgtc accatcaagt 180ctcctaggac tcctcgcagg
attacaggtg gtgtatttct tgtggacaaa aatcctaaca 240ataccgcaga
gtctagactc gtggtggact tctctcaatt ttctaggggg agcacccgtg
300tgtcctggcc aaaattcgca gtccccaacc tccaatcact caccaacctc
ttgtcctcca 360atttgtcctg gttatcgctg gatgtgtctg cggcgtttta
tcatcttcct cttcatcctg 420cttctatgcc tcatcttctt gttggttctt
ctggactatc aaggtatgtt gcccgtttgt 480cctctaattc caggatcatc
gaccaccagc acgggaccat gcaaaacctg tatgactacc 540cctcaaggaa
cctctatgta tccctcatgt tgttgtacca aaccttcgga cggaaattgc
600acctgtattc ccatcccatc atcctgggct ttcggaaaat tcctatggga
gtgggcctca 660gtccgtttct cctggctcag tttactagct ccatttgttc
agcggttcgt agggctttcc 720cccactgttt ggctttcagt tatatggatg
atgtggttct gggggccaag tctgttcagc 780atcttgagtc ccttcttgcc
tctgttacca cttttctttt ggctttgggt atacatttaa 84026279PRTArtificial
Sequencesynthetic polypeptide 26Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp
Pro Val Thr Asn Met Ser Pro Ser Ser Leu Leu Gly Leu 50 55 60 Leu
Ala Gly Leu Gln Val Val Tyr Phe Leu Trp Thr Lys Ile Leu Thr65 70 75
80 Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly
85 90 95 Gly Ala Pro Val Cys Pro Gly Gln Asn Ser Gln Ser Pro Thr
Ser Asn 100 105 110 His Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly
Tyr Arg Trp Met 115 120 125 Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe
Ile Leu Leu Leu Cys Leu 130 135 140 Ile Phe Leu Leu Val Leu Leu Asp
Tyr Gln Gly Met Leu Pro Val Cys145 150 155 160 Pro Leu Ile Pro Gly
Ser Ser Thr Thr Ser Thr Gly Pro Cys Lys Thr 165 170 175 Cys Met Thr
Thr Pro Gln Gly Thr Ser Met Tyr Pro Ser Cys Cys Cys 180 185 190 Thr
Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser 195 200
205 Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Val Arg Phe Ser
210 215 220 Trp Leu Ser Leu Leu Ala Pro Phe Val Gln Arg Phe Val Gly
Leu Ser225 230 235 240 Pro Thr Val Trp Leu Ser Val Ile Trp Met Met
Trp Phe Trp Gly Pro 245 250 255 Ser Leu Phe Ser Ile Leu Ser Pro Phe
Leu Pro Leu Leu Pro Leu Phe 260 265 270 Phe Trp Leu Trp Val Tyr Ile
275 27846DNAArtificial Sequencesynthetic nucleic acid 27atgcagtgga
attccactgc cttccaccaa actctgcaag atcccagagt acggggccta 60tactttcctg
ttggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cccttatcgt caatcttctc gaggattggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct gctcgtgtta caggcggggt
ttttcttgtt gacaaaagtc 240ctcacaatac cgcagagcct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgtgtc ttggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accagcacgg
gaccctgcag gacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgtt gtacaaaacc ttcggacgga 600aattgcactt gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgcttggct tttagctata tggatcatct ggtattgggg
gccaaatctg 780tacaacatct tgaatccatt tataccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84628281PRTArtificial
Sequencesynthetic polypeptide 28Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Phe Pro
Val Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser Pro Leu Ser Ser Ile Phe Ser Arg 35 40 45 Ile Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Lys Val65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Leu Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Arg Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Ala Trp Leu Leu Ala Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Ile Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 29846DNAArtificial Sequencesynthetic nucleic acid
29atgcagtgga attccactgc cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagctcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggattggg gaccctgcgc tgaacatggg
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgat gacaaaaatc 240ctcacaatgc cgcagagtct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgcgtc ctggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc tacttccagg gtcctcaaca accagcacgg
gaccctgcag gacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg caaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgtttggct ttcagttata tggatcatct ggtattgggg
gccaaatctg 780tacaacatct tgaatccatt tataccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84630281PRTArtificial
Sequencesynthetic polypeptide 30Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Ile Gly Asp
Pro Ala Leu Asn Met Gly Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Met Thr Lys Ile65 70 75
80 Leu Thr Met Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Arg Pro Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Leu
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Arg Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Ile Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 31846DNAArtificial Sequencesynthetic nucleic acid
31atgcagtgga attccactgc cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagctcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggattagg gaccctgcgc tgaacatgga
gaacatcgca 180tcaggattcc taggacccct tctcgcatta caggcggtgt
ttttcttgtt gacaaaaatc 240ctcacaatgc cacagagtct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgtgtc ttggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accagcacgg
gaccatgcaa aacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgtt gtacaaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg caaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgtttggct ttcagttata tggatgatgt ggtattgggg
accaagtctg 780tacagcatct tgagtccctt cttgcctctg ttaccacttt
tcttttggct ttgggtatac 840atttaa 84632281PRTArtificial
Sequencesynthetic polypeptide 32Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Ile Arg Asp
Pro Ala Leu Asn Met Glu Asn Ile Ala Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Ala Leu Gln Ala Val Phe Phe Leu Leu Thr Lys Ile65 70 75
80 Leu Thr Met Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Leu Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Met Met Trp Tyr Trp 245 250 255 Gly Pro Ser Leu Tyr Ser Ile Leu Ser
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Leu Phe Phe Trp Leu Trp Val
Tyr Ile 275 280 33846DNAArtificial Sequencesynthetic nucleic acid
33atgcagtgga attctacaac cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggactggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cacagagtct
agactcgtgg tggacttctc tcaattttct agggggagca 300cccgtgtgtc
ctggccaaaa ttcgcagtcc ccaacctcca atcactcacc aacctcttgt
360cctccgattt gtcctggcta tcgctggatg tgtctgcggc gttttatcat
cttcctcttc 420atcctgctgc tatgcctcat cttcttgttg gttcttctgg
actatcgagg tatgttgccc 480gtttgtcctc tacttccagg atcctcaaca
accagcacgg gaccatgccg gacctgcatg 540actaccgctc aaggaacctc
tatgtatccc tcatgttgct gtaccaaacc ttcggacgga 600agctgcactt
gtattcccat cccatcatcc tgggctttcg caaaattcct atgggagtgg
660gcctcagccc gtttctcctg gctcagttta ctagtgccat ttgttcagtg
gttcgtaggg 720ctttcccccg ctgtatggct ttcagttata tggatgattt
ggttttgggg gccaagtctg 780tacagcatct tgagtccctt tttaccgctg
ttaccaattt tcttttgtct ttgggtatac 840atttaa 84634281PRTArtificial
Sequencesynthetic polypeptide 34Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Leu Gly Leu Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Pro Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Ala Trp Leu Leu Ala Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 35846DNAArtificial Sequencesynthetic nucleic acid
35atgcagtgga attctacaac cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggactggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cacagagtct agactcgtgg
tggacttctc tcaattttct agggggaact 300accgtgtgtc ttggcctaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgcttc tatgcctcat cttcttgttg gttcttctgg actatcaagg
tatgttgccc 480gtttgtcccc taattccagg atcctcaaca accagcacgg
gaccatgcaa aacctgtatg 540actacccctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgcttggct tttggctata tggatcatct ggtattgggg
gccaaatctg 780tacaacatct tgaatccctt tttaccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84636281PRTArtificial
Sequencesynthetic polypeptide 36Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Thr Val Cys Leu Gly Leu Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Pro Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Ala Trp Leu Leu Ala Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 37846DNAArtificial Sequencesynthetic nucleic acid
37atgcagtgga attccacaac cttccaccaa actctgcagg atcccagagt caggggtctg
60tatcttcctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa tactgcctct
120cacatctcgt cagtcttctc gacgactggg gaccctgcac cgaacatgga
gaacatcaca 180tcaggattcc taggacccct gctcgtgtta caggcggggt
ttttcttgtt gacaaaaatc 240ctcacaatgc cacagagtct agactcgttg
tggacttctc tcaattttct agggggaaca 300ccagcgtgtc ttggccaaaa
ttcgcagtcc ccaaccccca atcactcacc aacctcttgc 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgcttc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc taattccagg atcctcaaca accagcacgg
gaccatgcaa aacctgtatg 540actacccctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgcttggct tttggctata tggatcatct ggtattgggg
gccaaatctg 780tacaacatct tgaatccctt tttaccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84638281PRTArtificial
Sequencesynthetic polypeptide 38Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Thr Ala Ser His Ile Ser Ser Val Phe Ser Thr 35 40 45 Thr Gly Asp
Pro Ala Pro Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Lys Ile65 70 75
80 Leu Thr Met Pro Gln Ser Leu Asp Ser Leu Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Pro Ala Cys Leu Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Pro Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Pro Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Ala Trp Leu Leu Ala Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 39846DNAArtificial Sequencesynthetic nucleic acid
39atgcagtgga attccactgc cttccaccaa actctgcagg atcccagagt caggggtctg
60tatctccctg ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggactggg gaccctgcac cgaacatgga
gaacatcaca 180tcaggattcc taggacccct gctcgtgtta caggcggtgt
ttttcttgtt gacaagaatc 240ctcacaatac cgcagagtct agactcgtgg
tggacttctc tcaattttct agggggaaca 300cccgtgtgtc ctggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgcttc tatgcctcat cttcttgttg gttcttctgg actatcaagg
tatgttgccc 480gtttgtcccc taattccagg atcctcaaca accagcacgg
gaccatgcaa aacctgtatg 540actacccctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagcg gttcgcaggg
720ctttccccca ctgtttggct ttcagttata tggatgattt ggttttgggg
gccaagtctg 780tacagcatct tgagtccctt tttaccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84640281PRTArtificial
Sequencesynthetic polypeptide 40Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp
Pro Ala Pro Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Val Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe
85 90 95 Leu Gly Gly Thr Pro Val Cys Pro Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Gln Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Ile
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Lys Thr Cys
Met Thr Thr Pro Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Arg Phe
Ala Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Met Ile Trp Phe Trp 245 250 255 Gly Pro Ser Leu Tyr Ser Ile Leu Ser
Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 41846DNAArtificial Sequencesynthetic nucleic acid
41atgcagtgga attccacaac cttccaccaa actctgcaag atcccagagt gagaggcctg
60tatttccctg ctggtggctc cagttcagga acagtaaacc ctgttctgac tactgcctct
120cccgtatcgt caatcttctc gaggattggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cgcagagtct agactcgttg
tggacttctc tcagttttcc aaggggcata 300ccagagtgca ctggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc tacttccagg atcctcaaca accagcacgg
gaccctgcag gacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg caaaattcct atgggagtgg 660gcctcagccc
gtttctcctg gctcagttta ctagtgccat ttgttcagtg gttcgtaggg
720ctttccccca ctgtttggct ttcagttata tggatcatct ggtattgggg
gccaaatctg 780tacaacatct tgaatccatt tataccgctg ttaccaattt
tcttttgtct ttgggtatac 840atttaa 84642281PRTArtificial
Sequencesynthetic polypeptide 42Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Phe Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Val Leu Thr
Thr Ala Ser Pro Val Ser Ser Ile Phe Ser Arg 35 40 45 Ile Gly Asp
Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75
80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Leu Trp Thr Ser Leu Ser Phe
85 90 95 Pro Arg Gly Ile Pro Glu Cys Thr Gly Gln Asn Ser Gln Ser
Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys
Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg Arg Phe Ile Ile Phe
Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile Phe Leu Leu Val Leu
Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160 Val Cys Pro Leu Leu
Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165 170 175 Arg Thr Cys
Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys 180 185 190 Cys
Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro 195 200
205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg
210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe
Val Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp
Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn Leu Tyr Asn Ile Leu Asn
Pro Phe Ile Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu Trp Val
Tyr Ile 275 280 43846DNAArtificial Sequencesynthetic nucleic acid
43atgcagtgga attccacaac cttccaccaa actctgcaag atcccagagt gagaggcctg
60tatttccctg ctggtggctc cagttcagga acagtaaacc ctgttctgac tactgcctct
120cccttatcgt caatcttctc gaggattggg gaccctgcgc tgaacatgga
gaacatcaca 180tcaggattcc taggacccct tctcgtgtta caggcggggt
ttttcttgtt gacaagaatc 240ctcacaatac cgcagagtct agactcgttg
tggacctctc tcagttttcc agggggcata 300ccagagtgca ctggccaaaa
ttcgcagtcc ccaacctcca atcactcacc aacctcttgt 360cctccaactt
gtcctggtta tcgctggatg tgtctgcggc gttttatcat cttcctcttc
420atcctgctgc tatgcctcat cttcttgttg gttcttctgg actatcgagg
tatgttgccc 480gtttgtcctc tacttccagg atcctcaaca accagcacgg
gaccctgcag gacctgtatg 540actaccgctc aaggaacctc tatgtatccc
tcatgttgct gtaccaaacc ttcggacgga 600aattgcacct gtattcccat
cccatcatcc tgggctttcg gaaaattcct atgggagtgg 660gcctcagtcc
gtttctcctg gctcagttta ctagctccat ttgttcagcg gttcgtaggg
720ctttccccca ctgtttggct ttcagttata tggatgatgt ggttctgggg
gccaagtctg 780ttcagcatct tgagtccctt cttgcctctg ttaccacttt
tcttttggct ttgggtatac 840atttaa 84644281PRTArtificial
Sequencesynthetic polypeptide 44Met Gln Trp Asn Ser Thr Thr Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Phe Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Val Leu Thr
Thr Ala Ser Pro Leu Ser Ser Ile Phe Ser Arg 35
40 45 Ile Gly Asp Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly Phe
Leu 50 55 60 Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu
Thr Arg Ile65 70 75 80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Leu Trp
Thr Ser Leu Ser Phe 85 90 95 Pro Gly Gly Ile Pro Glu Cys Thr Gly
Gln Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His Ser Pro Thr Ser
Cys Pro Pro Thr Cys Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu Arg
Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu Ile
Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met Leu Pro145 150 155 160
Val Cys Pro Leu Leu Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys 165
170 175 Arg Thr Cys Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser
Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile
Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp Glu
Trp Ala Ser Val Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Ala Pro
Phe Val Gln Arg Phe Val Gly225 230 235 240 Leu Ser Pro Thr Val Trp
Leu Ser Val Ile Trp Met Met Trp Phe Trp 245 250 255 Gly Pro Ser Leu
Phe Ser Ile Leu Ser Pro Phe Leu Pro Leu Leu Pro 260 265 270 Leu Phe
Phe Trp Leu Trp Val Tyr Ile 275 280 45846DNAArtificial
Sequencesynthetic nucleic acid 45atgcagtgga attccactgc cttccaccaa
actctgcagg atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagctcagga
acagtaaacc ctgctccgaa tattgcctct 120cacatctcgt caatctccgc
gaggattggg gaccctgcgc tgaacatgga gaacatcaca 180tcaggattcc
taggacccct tctcgcatta caggcggtgt ttttcttgtt gacaaaaatc
240ctcacaatgc cacagagtct agactcgtgg tggacttctc tcaattttct
agggggaact 300accgtgtgtc ttggcctaaa ttcgcagtcc ccaacctcca
atcactcacc aacctcttgt 360cctccaactt gtcctggtta tcgctggatg
tgtctgcggc gttttatcat cttcctcttc 420atcctgctgc tgtgcctcat
cttcttgttg gttcttctgg actatcgagg tatgttgccc 480gtttgtcctc
tacttccagg atcctcaaca accagcacgg gaccatgccg gacctgcatg
540actaccgctc aaggaacctc tatgtatccc tcatgttgct gtaccaaacc
ttcggacgga 600agctgcactt gtattcccat cccctcatcc tgggctttcg
gaaaattcct atgggagtgg 660gcctcagtcc gtttctcctg gctcagttta
ctagtgccat ttgttcagtg gttcgcaggg 720ctttccccca ctgtatggct
tttagttata tggatgatgt ggttctgggg gccaagtctg 780ttcagcatct
tgagtccctt cttgcctctg ttaccaattt tcttttgtct ttgggtatac 840atttaa
84646281PRTArtificial Sequencesynthetic polypeptide 46Met Gln Trp
Asn Ser Thr Ala Phe His Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val
Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25
30 Asn Pro Ala Pro Asn Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg
35 40 45 Ile Gly Asp Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly
Phe Leu 50 55 60 Gly Pro Leu Leu Ala Leu Gln Ala Val Phe Phe Leu
Leu Thr Lys Ile65 70 75 80 Leu Thr Met Pro Gln Ser Leu Asp Ser Trp
Trp Thr Ser Leu Asn Phe 85 90 95 Leu Gly Gly Thr Thr Val Cys Leu
Gly Leu Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His Ser Pro Thr
Ser Cys Pro Pro Thr Cys Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu
Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu
Ile Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met Leu Pro145 150 155
160 Val Cys Pro Leu Leu Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys
165 170 175 Arg Thr Cys Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro
Ser Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly Ser Cys Thr Cys
Ile Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp
Glu Trp Ala Ser Val Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Val
Pro Phe Val Gln Trp Phe Ala Gly225 230 235 240 Leu Ser Pro Thr Val
Trp Leu Leu Val Ile Trp Met Met Trp Phe Trp 245 250 255 Gly Pro Ser
Leu Phe Ser Ile Leu Ser Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile
Phe Phe Cys Leu Trp Val Tyr Ile 275 280 47846DNAArtificial
Sequencesynthetic nucleic acid 47atgcagtgga attccactgc cttccaccaa
actctgcagg atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagttcagga
acagtaaacc ctgctccgaa tattgcctct 120cccttatcgt caatcttctc
gacgactggg gaccctgcgc tgaacatgga gaacatcaca 180tcaggattcc
taggacccct tctcgtgtta caggcggggt ttttcttgtt gacaagaatc
240ctcacaatac cgcagagtct agactcgtgg tggacttctc tcaattttct
agggggagca 300cccgtgtgtc ttggccaaaa ttcgcagtcc ccaacctcca
atcactcacc aacctcttgt 360cctccaactt gtcctggtta tcgctggatg
tgtctgcggc gttttatcat cttcctcttc 420atcctgctgc tatgcctcat
cttcttgttg gttcttctgg actatcgagg tatgttgccc 480gtttgtcctc
taattccagg atcctcaaca accagcacgg gaccctgcag gacctgtatg
540actgccgctc aaggaacctc tatgtatccc tcatgttgct gtaccaaacc
ttcggacgga 600aattgcacct gtattcccat cccatcatcc tgggctttcg
caaaattcct atgggagtgg 660gcctcagccc gtttctcctg gctcagttta
ctagtgccat ttgttcagtg gttcgtaggg 720ctttccccca ctgtttggct
ttcagttata tggatcatct ggtattgggg gccaaatctg 780tacaacatct
tgaatccatt tataccgctg ttaccaattt tcttttgtct ttgggtatac 840atttaa
84648281PRTArtificial Sequencesynthetic polypeptide 48Met Gln Trp
Asn Ser Thr Ala Phe His Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val
Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25
30 Asn Pro Ala Pro Asn Ile Ala Ser Pro Leu Ser Ser Ile Phe Ser Thr
35 40 45 Thr Gly Asp Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly
Phe Leu 50 55 60 Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu
Leu Thr Arg Ile65 70 75 80 Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp
Trp Thr Ser Leu Asn Phe 85 90 95 Leu Gly Gly Ala Pro Val Cys Leu
Gly Gln Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His Ser Pro Thr
Ser Cys Pro Pro Thr Cys Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu
Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu
Ile Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met Leu Pro145 150 155
160 Val Cys Pro Leu Ile Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys
165 170 175 Arg Thr Cys Met Thr Ala Ala Gln Gly Thr Ser Met Tyr Pro
Ser Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys
Ile Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp
Glu Trp Ala Ser Ala Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Val
Pro Phe Val Gln Trp Phe Val Gly225 230 235 240 Leu Ser Pro Thr Val
Trp Leu Ser Val Ile Trp Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn
Leu Tyr Asn Ile Leu Asn Pro Phe Ile Pro Leu Leu Pro 260 265 270 Ile
Phe Phe Cys Leu Trp Val Tyr Ile 275 280 49846DNAArtificial
Sequencesynthetic nucleic acid 49atgcagtgga attccacaac cttccaccaa
actctgcagg atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagttcagga
acagtaaacc ctgctccgaa tactgcctct 120cacatctcgt cagtcttctc
gacgactggg gaccctgcac cgaacatgga gaacatcaca 180tcaggattcc
taggacccct gctcgtgtta caggcggggt ttttcttgtt gacaaaaatc
240ctcacaatgc cacagagtct agactcgttg tggacttctc tcaattttct
agggggaaca 300ccagcgtgtc ttggccaaaa ttcgcagtcc ccaacctcca
atcactcacc aacctcttgt 360cctccaactt gtcctggtca tcgctggatg
tgtctgcggc gttttatcat cttcctcttc 420atcctgctgc tatgcctcat
cttcttgttg gttcttctgg actatcgagg tatgttgccc 480gtttgtcctc
taattccagg atcctcaaca accagcacgg gaccatgcaa aacctgtatg
540actacccctc aaggaacctc tatgtatccc tcatgttgct gtaccaaacc
ttcggacgga 600aattgcacct gtattcccat cccatcatcc tgggctttcg
gaaaattcct atgggagtgg 660gcctcagccc gtttctcctg gctcagttta
ctagtgccat ttgttcagtg gttcgtaggg 720ctttccccca ctgcttggct
tttggctata tggatcatct ggtattgggg gccaaatctg 780tacaacatct
tgaatccctt tttaccgctg ttaccaattt tcttttgtct ttgggtatac 840atttaa
84650281PRTArtificial Sequencesynthetic polypeptide 50Met Gln Trp
Asn Ser Thr Thr Phe His Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val
Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25
30 Asn Pro Ala Pro Asn Thr Ala Ser His Ile Ser Ser Val Phe Ser Thr
35 40 45 Thr Gly Asp Pro Ala Pro Asn Met Glu Asn Ile Thr Ser Gly
Phe Leu 50 55 60 Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu
Leu Thr Lys Ile65 70 75 80 Leu Thr Met Pro Gln Ser Leu Asp Ser Leu
Trp Thr Ser Leu Asn Phe 85 90 95 Leu Gly Gly Thr Pro Ala Cys Leu
Gly Gln Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His Ser Pro Thr
Ser Cys Pro Pro Thr Cys Pro Gly His Arg 115 120 125 Trp Met Cys Leu
Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu
Ile Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met Leu Pro145 150 155
160 Val Cys Pro Leu Ile Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys
165 170 175 Lys Thr Cys Met Thr Thr Pro Gln Gly Thr Ser Met Tyr Pro
Ser Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys
Ile Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp
Glu Trp Ala Ser Ala Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Val
Pro Phe Val Gln Trp Phe Val Gly225 230 235 240 Leu Ser Pro Thr Ala
Trp Leu Leu Ala Ile Trp Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn
Leu Tyr Asn Ile Leu Asn Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile
Phe Phe Cys Leu Trp Val Tyr Ile 275 280 51846DNAArtificial
Sequencesynthetic nucleic acid 51atgcagtgga attccacaac cttccaccaa
actctgcagg atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagttcagga
acagtaaacc ctgctccgaa tactgcctct 120cacatctcgt cagtcttctc
gacgactggg gaccctgcac cgaacatgga gaacatcaca 180tcaggattcc
taggacccct gctcgtgtta caggcggggt ttttcttgtt gacaaaaatc
240ctcacaatgc cacagagtct agactcgttg tggacttctc tcaattttct
agggggaaca 300ccagcgtgtc ttggccaaaa ttcgcagtcc ccaacctcca
atcactcacc aacctcttgt 360cctccaactt gtcctggtca tcgctggatg
tgtctgcggc gttttatcat cttcctcttc 420atcctgctgc tatgcctcat
cttcttgttg gttcttctgg actatcgagg tatgttgccc 480gtttgtcctc
taattccagg atcctcaaca accagcacgg gaccatgcaa aacctgtatg
540actacccctc aaggaacctc tatgtatccc tcatgttgct gtaccaaacc
ttcggacgga 600aattgcacct gtattcccat cccatcatcc tgggctttcg
gaaaattcct atgggagtgg 660gcctcagccc gtttctcctg gctcagttta
ctagtgccat ttgttcagtg gttcgtaggg 720ctttccccca ctgcttggct
tttggctata tggatcatct ggtattgggg gccaaatctg 780tacaacatct
tgaatccctt tttaccgctg ttaccaattt tcttttgtct ttgggtatac 840atttaa
84652281PRTArtificial Sequencesynthetic polypeptide 52Met Gln Trp
Asn Ser Thr Ala Phe His Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val
Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25
30 Asn Pro Ala Pro Asn Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg
35 40 45 Ile Gly Asp Pro Ala Leu Asn Met Glu Asn Ile Thr Ser Gly
Phe Leu 50 55 60 Gly Pro Leu Leu Ala Leu Gln Ala Val Phe Phe Leu
Leu Thr Lys Ile65 70 75 80 Leu Thr Met Pro Gln Ser Leu Asp Ser Trp
Trp Thr Ser Leu Asn Phe 85 90 95 Leu Gly Gly Thr Thr Val Cys Leu
Gly Gln Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His Ser Pro Thr
Ser Cys Pro Pro Thr Cys Pro Gly Tyr Arg 115 120 125 Trp Met Cys Leu
Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu
Ile Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met Leu Pro145 150 155
160 Val Cys Pro Leu Ile Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys
165 170 175 Lys Thr Cys Met Thr Thr Ala Gln Gly Thr Ser Met Tyr Pro
Ser Cys 180 185 190 Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys
Ile Pro Ile Pro 195 200 205 Ser Ser Trp Ala Phe Gly Lys Phe Leu Trp
Glu Trp Ala Ser Ala Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Ala
Pro Phe Val Gln Arg Phe Ala Gly225 230 235 240 Leu Ser Pro Thr Ala
Trp Leu Leu Ala Ile Trp Ile Ile Trp Tyr Trp 245 250 255 Gly Pro Asn
Leu Tyr Asn Ile Met Asn Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile
Phe Phe Cys Leu Trp Val Tyr Ile 275 280 53846DNAArtificial
Sequencesynthetic nucleic acid 53atgcagtgga attccactgc cttccaccaa
actctgcagg atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagttcagga
acagtaaacc ctgctccgaa tactgcctct 120cacatctcgt cagtcttctc
gacgactggg gaccctgcac cgaacatgga gaacatcaca 180tcaggattcc
taggacccct gctcgtgtta caggcggggt ttttcttgtt gacaaaaatc
240ctcacaatgc cacagagtct agactcgttg tggacttctc tcaattttct
agggggaaca 300ccagcgtgtc ttggccaaaa ttcgcagtcc ccaacctcca
atcactcacc aacctcttgt 360cctccaactt gtcctggtta tcactggatg
tgtctgcggc gttttatcat cttcctcttc 420atcctgctgc tatgcctcat
cttcttgttg gttcttctgg actatcgagg tatgttgccc 480gtttgtcctc
tacttccagg atcatcgacc accagcacgg gaccatgcaa aacctgcacg
540atccctgctc aaggaacctc tttgattccc tcatgttgtt gtacaaaacc
ttcggacgga 600aattgcactt gtattcccat cccatcgtct tgggctttcg
caaaattcct atgggagtgg 660gcctcagccc gtttctcctg gctcagttta
ctagtgccat ttgttcagcg gttcgcaggg 720ctttccccca ctgtttggct
ttcagttata tggatgattt ggttttgggg gccaagtctg 780tacagcatct
tgagtccctt tttaccgctg ttaccaattt tcttttgtct ttgggtatac 840atttaa
84654281PRTArtificial Sequencesynthetic polypeptide 54Met Gln Trp
Asn Ser Thr Ala Phe His Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val
Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25
30 Asn Pro Ala Pro Asn Thr Ala Ser His Ile Ser Ser Val Phe Ser Thr
35 40 45 Thr Gly Asp Pro Ala Pro Asn Met Glu Asn Ile Thr Ser Gly
Phe Leu 50 55 60 Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu
Leu Thr Lys Ile65 70 75 80 Leu Thr Met Pro Gln Ser Leu Asp Ser Leu
Trp Thr Ser Leu Asn Phe 85 90 95 Leu Gly Gly Thr Pro Ala Cys Leu
Gly Gln Asn Ser Gln Ser Pro Thr 100 105 110 Ser Asn His Ser Pro Thr
Ser Cys Pro Pro Thr Cys Pro Gly Tyr His 115 120 125 Trp Met Cys Leu
Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu 130 135 140 Cys Leu
Ile Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met Leu Pro145 150 155
160 Val Cys Pro Leu Leu Pro Gly Ser Ser Thr Thr Ser Thr Gly Pro Cys
165 170 175 Lys Thr Cys Thr Ile Pro Ala Gln Gly Thr Ser Leu Ile Pro
Ser Cys 180 185
190 Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro
195 200 205 Ser Ser Trp Ala Phe Ala Lys Phe Leu Trp Glu Trp Ala Ser
Ala Arg 210 215 220 Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln
Arg Phe Ala Gly225 230 235 240 Leu Ser Pro Thr Val Trp Leu Ser Val
Ile Trp Met Ile Trp Phe Trp 245 250 255 Gly Pro Ser Leu Tyr Ser Ile
Leu Ser Pro Phe Leu Pro Leu Leu Pro 260 265 270 Ile Phe Phe Cys Leu
Trp Val Tyr Ile 275 280 55840DNAArtificial Sequencesynthetic
nucleic acid 55atgcagtgga attctactgc cttccaccaa actctgcagg
atcccagagt caggggtctg 60tatcttcctg ctggtggctc cagttcagga acagtaaacc
ctgctccgaa tattgcctct 120cacatctcgt caatctccgc gaggactggg
gaccctgtga cgaacatgtc accatcaagt 180ctcctaggac tcctagcagg
attacaggtg gtgtatttct tgtggacaaa aatcctaaca 240ataccgcaga
gtctagactc gtggtggact tctctcaatt ttctaggggg agcacccgtg
300tgtcctggcc aaaattcgca gcccccaacc cccaatcact caccaacctc
ttgtccttca 360acttgtcctg ggtatcgctg gatgcgtctg tggcgtttta
tcatcttcct cttcatcctg 420ctgctatgcc tcatcttctt gttggttctt
ctggactatc gaggtgtgtt gcccgtttgt 480cctccaattc caggatcctc
aacaaccagc acgggaccat gcaaaacctg tatgactacc 540gctcaaggaa
cctctatgta tccctcatgt tgttgtacaa aaccttcgga cggaaattgc
600acctgtattc ccatcccatc atcctgggct ttcggaaaat tcctatggga
gtgggcctca 660gcccgtttct cctggctcag tttactagtg ccatttgttc
agtggttcgt agggctttcc 720cccactgctt ggcttttggc tacatggatc
atctggtatt gggggccaaa tctgtacaac 780atcttgaatc cctttttacc
gctgttacca attttctttt gtctttgggt atacatttaa 84056279PRTArtificial
Sequencesynthetic polypeptide 56Met Gln Trp Asn Ser Thr Ala Phe His
Gln Thr Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro
Ala Gly Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn
Ile Ala Ser His Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp
Pro Val Thr Asn Met Ser Pro Ser Ser Leu Leu Gly Leu 50 55 60 Leu
Ala Gly Leu Gln Val Val Tyr Phe Leu Trp Thr Lys Ile Leu Thr65 70 75
80 Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly
85 90 95 Gly Ala Pro Val Cys Pro Gly Gln Asn Ser Gln Pro Pro Thr
Pro Asn 100 105 110 His Ser Pro Thr Ser Cys Pro Ser Thr Cys Pro Gly
Tyr Arg Trp Met 115 120 125 Arg Leu Trp Arg Phe Ile Ile Phe Leu Phe
Ile Leu Leu Leu Cys Leu 130 135 140 Ile Phe Leu Leu Val Leu Leu Asp
Tyr Arg Gly Val Leu Pro Val Cys145 150 155 160 Pro Pro Ile Pro Gly
Ser Ser Thr Thr Ser Thr Gly Pro Cys Lys Thr 165 170 175 Cys Met Thr
Thr Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys Cys Cys 180 185 190 Thr
Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser 195 200
205 Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg Phe Ser
210 215 220 Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly
Leu Ser225 230 235 240 Pro Thr Ala Trp Leu Leu Ala Thr Trp Ile Ile
Trp Tyr Trp Gly Pro 245 250 255 Asn Leu Tyr Asn Ile Leu Asn Pro Phe
Leu Pro Leu Leu Pro Ile Phe 260 265 270 Phe Cys Leu Trp Val Tyr Ile
275 57840DNAArtificial Sequencesynthetic nucleic acid 57atgcagtgga
attctactgc cttccaccaa actctgcagg atcccagagt caggggtctg 60tatcttcctg
ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggactggg gaccctgtga cgaacatgtc
accatcaagt 180ctcctaggac tcctcgcagg attacaggtg gtgtatttct
tgtggacaaa aatcctaaca 240ataccgcaga gtctagactc gtggtggact
tctctcaatt ttctaggggg agcacccgtg 300tgtcctggcc aaaattcgca
gtccccaacc tccaatcact caccaacctc ttgtcctcca 360acttgtcctg
gttatcgctg gatgtgtctg cggcgtttta tcatcttcct cttcatcctg
420ctgctatgcc tcatcttctt gttggttctt ctggactatc gaggtatgtt
gcccgtttgt 480cctctacttc caggatcctc aacaaccagc acgggaccct
gcaggacctg tatgactacc 540gctcaaggaa cctctatgta tccctcatgt
tgctgtacca aaccttcgga cggaaattgc 600acctgtattc ccatcccatc
atcctgggct ttcgcaaaat tcctatggga gtgggcctca 660gcccgtttct
cctggctcag tttactagtg ccatttgttc agtggttcgt agggctttcc
720cccactgttt ggctttcagt tatatggatc atctggtatt gggggccaaa
tctgtacaac 780atcttgagtc catttatacc gctgttacca attttctttt
gtctttgggt atacatttaa 84058279PRTArtificial Sequencesynthetic
polypeptide 58Met Gln Trp Asn Ser Thr Ala Phe His Gln Thr Leu Gln
Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser
Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn Ile Ala Ser His
Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp Pro Val Thr Asn
Met Ser Pro Ser Ser Leu Leu Gly Leu 50 55 60 Leu Ala Gly Leu Gln
Val Val Tyr Phe Leu Trp Thr Lys Ile Leu Thr65 70 75 80 Ile Pro Gln
Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly 85 90 95 Gly
Ala Pro Val Cys Pro Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn 100 105
110 His Ser Pro Thr Ser Cys Pro Pro Thr Cys Pro Gly Tyr Arg Trp Met
115 120 125 Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu
Cys Leu 130 135 140 Ile Phe Leu Leu Val Leu Leu Asp Tyr Arg Gly Met
Leu Pro Val Cys145 150 155 160 Pro Leu Leu Pro Gly Ser Ser Thr Thr
Ser Thr Gly Pro Cys Arg Thr 165 170 175 Cys Met Thr Thr Ala Gln Gly
Thr Ser Met Tyr Pro Ser Cys Cys Cys 180 185 190 Thr Lys Pro Ser Asp
Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser 195 200 205 Trp Ala Phe
Ala Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg Phe Ser 210 215 220 Trp
Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser225 230
235 240 Pro Thr Val Trp Leu Ser Val Ile Trp Ile Ile Trp Tyr Trp Gly
Pro 245 250 255 Asn Leu Tyr Asn Ile Leu Ser Pro Phe Ile Pro Leu Leu
Pro Ile Phe 260 265 270 Phe Cys Leu Trp Val Tyr Ile 275
59280PRThepatitis B 59Met Gln Trp Asn Ser Thr Thr Phe His Gln Thr
Leu Gln Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Phe Pro Ala Gly
Gly Ser Ser Ser Gly Thr Val 20 25 30 Asn Pro Val Leu Thr Thr Ala
Ser Pro Leu Ser Ser Ile Phe Ser Arg 35 40 45 Ile Gly Asp Pro Ala
Leu Asn Met Glu Asn Ile Thr Ser Gly Phe Leu 50 55 60 Gly Pro Leu
Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile65 70 75 80 Leu
Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe 85 90
95 Leu Gly Gly Thr Thr Val Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr
100 105 110 Ser Asn His Ser Pro Thr Ser Cys Pro Pro Thr Cys Pro Gly
Tyr Arg 115 120 125 Trp Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile
Leu Leu Leu Cys 130 135 140 Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr
Gln Gly Met Leu Pro Val145 150 155 160 Cys Pro Leu Ile Pro Gly Ser
Ser Thr Thr Ser Thr Gly Pro Cys Arg 165 170 175 Thr Cys Met Thr Thr
Ala Gln Gly Thr Ser Met Tyr Pro Ser Cys Cys 180 185 190 Cys Thr Lys
Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser 195 200 205 Ser
Trp Ala Phe Gly Lys Phe Leu Trp Glu Trp Ala Ser Ala Arg Phe 210 215
220 Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly
Leu225 230 235 240 Ser Pro Thr Val Trp Leu Ser Val Ile Trp Met Met
Trp Tyr Trp Gly 245 250 255 Pro Ser Leu Tyr Ser Ile Leu Ser Pro Phe
Leu Pro Leu Leu Pro Ile 260 265 270 Phe Phe Cys Leu Trp Val Tyr Ile
275 280 6030DNAhepatitis B 60tatgactacc gctcaaggaa cctctatgta
306159DNAhepatitis B 61accatgcaaa cctgtatgac taccgctcaa ggaacctcta
tgtatccctc atgttgttg 596260DNAhepatitis B 62accctgcagg acctgtatga
ctaccgctca aggaacctct atgtatccct catgttgctg 606360DNAhepatitis B
63caattgcaga caatgtatga ctaccgctca aggaacctct atgtatcctt actgttgttg
606421DNAArtificial Sequencevector 64gcagctcctt gctcctaaca g
216521DNAArtificial Sequencevector 65gtatcacgag gccctttcgt c
216620DNAArtificial Sequencevector 66gctgacagac taacagactg
206720DNAArtificial Sequencevector 67aacagatggc tggcaactag
2068837DNAArtificial Sequencesynthetic nucleic acid 68atgcagtgga
attctactgc cttccaccaa actctgcagg atcccagagt caggggtctg 60tatcttcctg
ctggtggctc cagttcagga acagtaaacc ctgctccgaa tattgcctct
120cacatctcgt caatctccgc gaggactggg gaccctgtga cgaacatgtc
accatcaagt 180ctcctaggac tcctcgcagg attacaggtg gtgtatttct
tgtggacaaa aatcctaaca 240ataccgcaga gtctagactc gtggtggact
tctctcaatt ttctaggggg agcacccgtg 300tgtcctggcc aaaattcgca
gtccccaacc tccaatcact caccaacctc ttgtcctcca 360atttgtcctg
gttatcgctg gatgtgtctg cggcgtttta tcatcttcct cttcatcctg
420cttctatgcc tcatcttctt gttggttctt ctggactatc aaggtatgtt
gcccgtttgt 480cctctaattc caggatcatc gaccaccagc acgggaccat
gcaaaacctg tatgactacc 540cctcaaggaa cctctatgta tccctcatgt
tgttgtacca aaccttcgga cggaaattgc 600acctgtattc ccatcccatc
atcctgggct ttcggaaaat tcctatggga gtgggcctca 660gtccgtttct
cctggctcag tttactagct ccatttgttc agcggttcgt agggctttcc
720cccactgttt ggctttcagt tatatggatg atgtggttct gggggccaag
tctgttcagc 780atcttgagtc ccttcttgcc tctgttacca cttttctttt
ggctttgggt atacatt 83769279PRTArtificial Sequencesynthetic
polypeptide 69Met Gln Trp Asn Ser Thr Ala Phe His Gln Thr Leu Gln
Asp Pro Arg1 5 10 15 Val Arg Gly Leu Tyr Leu Pro Ala Gly Gly Ser
Ser Ser Gly Thr Val 20 25 30 Asn Pro Ala Pro Asn Ile Ala Ser His
Ile Ser Ser Ile Ser Ala Arg 35 40 45 Thr Gly Asp Pro Val Thr Asn
Met Ser Pro Ser Ser Leu Leu Gly Leu 50 55 60 Leu Ala Gly Leu Gln
Val Val Tyr Phe Leu Trp Thr Lys Ile Leu Thr65 70 75 80 Ile Pro Gln
Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly 85 90 95 Gly
Ala Pro Val Cys Pro Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn 100 105
110 His Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met
115 120 125 Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu
Cys Leu 130 135 140 Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met
Leu Pro Val Cys145 150 155 160 Pro Leu Ile Pro Gly Ser Ser Thr Thr
Ser Thr Gly Pro Cys Lys Thr 165 170 175 Cys Met Thr Thr Pro Gln Gly
Thr Ser Met Tyr Pro Ser Cys Cys Cys 180 185 190 Thr Lys Pro Ser Asp
Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser 195 200 205 Trp Ala Phe
Gly Lys Phe Leu Trp Glu Trp Ala Ser Val Arg Phe Ser 210 215 220 Trp
Leu Ser Leu Leu Ala Pro Phe Val Gln Arg Phe Val Gly Leu Ser225 230
235 240 Pro Thr Val Trp Leu Ser Val Ile Trp Met Met Trp Phe Trp Gly
Pro 245 250 255 Ser Leu Phe Ser Ile Leu Ser Pro Phe Leu Pro Leu Leu
Pro Leu Phe 260 265 270 Phe Trp Leu Trp Val Tyr Ile 275
* * * * *